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RADIOLOGICAL, PHYSIOLOGICAL AND PSYCHOSOCIAL VARIABLES
BEFORE AND AFTER UTERINE ARTERY EMBOLIZATION FOR FIBROIDS.

Elizabeth Kagan Arleo, Michael G. Tal, and Robin M. Masheb. Vascular and
Interventional Radiology Division, Department of Diagnostic Radiology, and Department
of Psychiatry, Yale University School of Medicine, New Haven, CT.

Purpose: To investigate MRI-determined uterine and fibroid size and location, and
fibroid-related symptoms, including quality of life and sexual function, in women with
symptomatic fibroids before and after uterine artery embolization (UAE), as well as
changing trends in gynecologists’ opinion of the procedure.

Methods: Fifty-two women underwent pelvic MRI within four weeks of and six months
post-procedure, from which uterine and fibroid size and location were noted. Women also
completed a self-report questionnaire within four weeks before and one to six months
after the procedure; the questionnaire investigated the frequency of fibroid-related
symptoms, as well as quality of life and sexual function via the Short Form-36 (SF-36)
and Female Sexual Function Index (FSFI). In addition, over a four year period, forty-two
women completed a telephone survey in which each was asked about her gynecologist’s
initial opinion of UAE and about who initiated discussion of UAE.

Results: At baseline, women with symptomatic fibroids had worse quality of life and
sexual function scores than healthy controls (p<.05). Pre-UAE, MRI-determined uterine
and fibroid volumes were significantly correlated with urinary frequency/urgency (p<.02)

and some aspects of quality of life (p<.04), but not with other fibroid-related symptoms
or sexual function. No significant differences with respect to fibroid-related symptoms
were found between patients with or without subserosal or submucosal fibroids. After
UAE, uterine and fibroid volumes significantly decreased (pc.03), as did urinary and pain
symptoms (pc.003), as well as several aspects of quality of life (pc.005). In addition,
more gynecologists had a favorable opinion of and were offering UAE than two years
previously, (pc.05).

Conclusions: Women with symptomatic fibroids had impaired quality of life and sexual
function, several aspects of which were correlated with uterine and fibroid volumes.
Treatment with UAE, increasingly accepted by gynecologists, can significantly reduce
uterine and fibroid volume and improve fibroid-related symptoms.
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INTRODUCTION
“The available evidence on the management of uterine leiomyomata is of poor
quality. Patients, clinicians, and policy makers do not have the data needed to
make informed decisions about appropriate treatment. Given the prevalence of
this condition and its substantial impact on women’s lives, obtaining these data
should be a high research priority.”
— Myers et ai, 2002 (1)

Uterine fibroids - also known as myoma, leiomyoma, and leiomyomata - are one
of the most common conditions affecting women of reproductive age, with prevalence
ranging from 20-77% (2). Thirty-five to fifty percent of women with fibroids are
symptomatic, experiencing menorrhagia, pain (dysmenorrhea, dyspareunia), pressurerelated symptoms (urinary frequency/urgency, constipation, bloating) and/or reproductive
difficulties (infertility, miscarriage) (3). These benign tumors, which arise from the
smooth muscle cells of the uterus, typically regress with menopausal decrease in steroid
hormones. However, women taking hormone replacement therapy may continue to
experience fibroid-related symptoms. The diagnosis of fibroids is made by history,
pelvic/abdominal examination, and pelvic ultrasound or Magnetic Resonance Imaging
(MRI).
Despite the prevalence of uterine fibroids and their considerable effect on
women’s lives, and despite cell physiologic advances including the identification of 145
genes involved in fibroid growth and development (4), a recent systematic literature
review concluded that there is little high-quality evidence with which to answer basic
questions about fibroid treatment strategies (1). Therefore, the purpose of this research
was to use quantitative MRI data and validated instruments to establish baseline
radiological, physiological and psychosocial characteristics of premenopausal women

2

with symptomatic uterine fibroids and to follow these variables after treatment with
uterine artery embolization (UAE), a relatively new procedure in the fibroid treatment
armamentarium.

Fibroid-related symptoms
Although fibroids can cause a number of symptoms, exactly how they do so is
unclear. One theory about the cause of bleeding symptoms is that fibroids may increase
the number, but impede the function, of uterine blood vessels; another is that the presence
of fibroids may impede the ability of the uterus to contract, thus causing inefficient
expulsion of menstrual material or impairing the ability of uterine arteries to clamp down
(5). The mass effect of fibroids (i.e., compressing the urinary bladder) is widely believed
to be the mechanism by which fibroids cause urinary symptoms. However, anecdotal
evidence from post-UAE patients that improvement in urinary symptoms precedes
significant shrinkage in fibroid volume suggests that other mechanisms may play a role
as well (6). The etiology of fibroid-related pain, including dysmenorrhea and
dyspareunia, may be related to mass effect as well, or in some cases may be a side effect
of attempted medical treatment (e.g., GnRH analogs, which may alter normal serum
estrogen levels, can cause vaginal epithelial atrophy, decreased lubrication, and thus
sexual pain).
In addition, fibroid-related symptoms are typically thought to be a function of
size, location, and number of fibroids. In terms of size, the risk of fibroid-related
symptoms, especially bleeding, is thought to increase with leiomyoma volume (7). In
terms of location, menorrhagia has been attributed to intramural and submucosal fibroids.
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whereas pelvic pain or pressure is more often attributed to intramural or subserosal
fibroids (8). In terms of number of fibroids, the impact appears to be chronically
undocumented, given that a recent systematic review of the literature on surgical and
non-surgical management of fibroids found that 70% of studies on invasive treatments
did not provide information on the number of leiomyomata (1).
The decision to treat symptomatic fibroids often is made based on uterine or
fibroid size, or fibroid location, despite the fact that the relationship between these
variables is not well established. For example, whereas it is known that the severity of
endometriosis-related symptoms does not necessarily correlate with the amount (3) but
does correlate with the location of endometriosis (9), it is not known whether the severity
of fibroid-related symptoms necessarily correlates with uterine or fibroid size, or fibroid
location within the uterus. This information is clinically relevant for the evidence-based
treatment decision-making. The postulated association between submucosal fibroids and
heavy bleeding (7), widely accepted clinically, often leads to hysteroscopic resection of
fibroids located submucosally. Alternatively, a patient undergoing myomectomy or
uterine artery embolization (UAE) may be counseled on the extent to which she may
expect her fibroid-related symptoms to improve based on the location of her fibroids (10).
The first aim of this research, therefore, was to investigate the relationship between
baseline MRI-determined total uterine volume, largest fibroid volume and fibroid
location, and fibroid-related symptoms in premenopausal women with symptomatic
uterine fibroids.
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Quality of life and sexual function
The increased awareness of subjective well-being as a critical factor in health
outcomes research has led to a proliferation of studies utilizing health-related quality-oflife (HRQOL) measures for assessing subjective well-being. HRQOL measures fall into
two categories: disease/disorder-specific, or generic, such as the Medical Outcomes
Study Short Form-36 Health Survey (SF-36) (11), a well-established generic HRQOL
measure. However, to date, minimal data exists characterizing the quality of life,
including sexual function, of women with leiomyomata by either method. Spies et al (12)
developed a fibroid-specific version of the SF-36 and found that women with fibroids
experienced lower health-related quality of life, as well as diminished sexual function,
than normal controls, but to our knowledge, no generic HRQOL measure has been
applied to establish baseline characteristics of women with fibroids alone.
A number of theories have been proposed to explain how fibroids cause sexual
dysfunction. The mass effect theory suggests that uterine fibroids can have a direct
mechanical influence on women’s sexual function by making it difficult for the uterus to
elevate and enlarge during arousal and contract during orgasm (13). It has also been
hypothesized that fibroid-related vascular changes can have a direct effect on women’s
sexual function as well (i.e., vessels feeding fibroids “stealing” blood from pelvic organs)
(14). In a paper on an animal model of vasculogenic female sexual dysfunction,
Goldstein et al (15) reported that “vaginal engorgement and clitoral erectile insufficiency
syndromes...exist when during sexual stimulation abnormal arterial circulation into the
vagina or clitoris, usually from atherosclerotic vascular disease, interferes with normal
vascular physiologic processes. Clinical symptoms may include delayed vaginal
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engorgement, diminished vaginal lubrication, pain or discomfort with intercourse,
diminished vaginal sensation, diminished vaginal orgasm, diminished clitoral sensation
or diminished clitoral orgasm.” If fibroid neovascularization creates an abnormal arterial
circulation into the vagina or clitoris, and/or a state of relative chronic ischemia of the
pelvic organs, then this may be another possible mechanism by which fibroids cause
sexual dysfunction.
Fibroids may also have an indirect biological influence on sexual function.
Menorrhagia secondary to fibroids can cause iron-deficiency anemia, which may
contribute to fatigue and thus negatively affect sexual desire. In addition, the side effects
of medical therapies for fibroids, such as GnRH analogs, may alter normal serum
estrogen levels, which can cause vaginal epithelial atrophy, decreased lubrication, and
thus sexual pain. Fibroids may have an indirect psychological influence on sexual
function as well. Abdominal enlargement secondary to fibroids may lead to detrimental
changes in body- and self-image, feelings of being less attractive or sexy, and depression.
Women may fear being rejected sexually, or conversely, worries about bulk, bladder and
bowel dysfunction, or vaginal bleeding during intercourse may cause them to reject
sexual activity. Reports from focus groups by Spies et al (12) corroborate both these
possibilities: “Dissatisfaction with one’s appearance also had an impact on sexual
function as some women in the focus groups “did not feel attractive”...[In addition,
women stated that they ] avoided sexual relations because of menorrhagia related to their
leiomyomata.” Another hypothesis is that dyspareunia might lead a woman with fibroids
to think that she has to endure pain with intercourse to satisfy her partner, or alternatively
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may lead to avoidance of sexual activity. Failure to express these concerns to a partner
may then cause difficulties in interpersonal relationships.
Given that fibroids can have profound direct and indirect biological and
psychological influences on sexual function, and quality of life, the second aim of this
research was to characterize the quality of life and sexual function of premenopausal
women seeking interventional treatment for symptomatic uterine fibroids.

Fibroid treatment options
Historically, the treatment of fibroids has been surgical, with surgical treatment
options including hysterectomy and myomectomy, and more recently, transvaginal
resection of fibroids (16), endometrial ablation (17), laparoscopic-directed thermal
coagulation (18), laser coagulation (19), cryotherapy (20), and MRI-guided focused
ultrasound surgery (21). Hysterectomy is currently the most common surgical treatment
for women with uterine fibroids, and fibroids are the number one discharge diagnosis for
hysterectomy: of the estimated 600,000 hysterectomies performed annually in the United
States, 40% are performed for fibroids (22). Myomectomy is the second most common
surgical treatment for women with fibroids: an estimated 35,000 myomectomies are
performed annually, including hysteroscopic myomectomies (to remove submucosal
fibroids), laparoscopic myomectomies (to remove fibroids located serosally), and
abdominal myomectomy (for fibroids in all locations) (23). However, since neither
hysterectomy nor myomectomy is an ideal solution, nonsurgical treatments have been in
high demand. Medical treatment options include GnRH analogs (24), gestrione (25), and
low-dose mifepristone (26). However, many women are unresponsive to such medical
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treatments or experience symptom recurrence after cessation of treatment (27). Given
these limitations, UAE - first described as a treatment for fibroids by Ravina et al in
1995 (28), but utilized for twenty years preceding for the treatment of post-partum
hemorrhage - has been increasing in popularity. To date, over 30.000 UAEs have been
performed worldwide to treat fibroids (29).
Hysterectomy, myomectomy, and uterine artery embolization each have their
advantages and disadvantages. In terms of overall success rates - defined as marked or
complete resolution of fibroid-related symptoms, requiring no further treatment - there
are notable differences: hysterectomy offers the advantage of complete cure by virtue of
removing the fibroid uterus, in contrast to overall success rates of 75% for myomectomy
(30) and 85-94% for UAE (31). Hysterectomy, however, is a major surgical procedure,
involves several days of hospitalization and up to six weeks of convalescence, and results
in permanent loss of the uterus and fertility. While myomectomy preserves the uterus, it
is still major abdominal surgery associated with hospital and recovery times similar to
hysterectomy, and with the potential for formation of painful, fertility-impairing
abdominal adhesions. In contrast, UAE preserves the uterus, in the context of shorter
hospital (<24 hours) and recovery times (1-2 weeks). Using ACOG’s (American College
of Obstetricians/Gynecologists) definitions for perioperative complications, the overall
morbidity of UAE has been reported to be 5%, compared to an overall morbidity of
38.6% for myomectomies and 40.1% for hysterectomies (31). Furthermore, lifethreatening events - defined as cardiopulmonary arrest, resuscitation, unplanned
admission to an intensive care unit, or death - have been reported to occur in 0.5% of
UAEs, in contrast to 1.5% of myomectomies and 1.0% of hysterectomies (31). However,
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some reports have found that pregnancy after UAE may be complicated by higher rates of
C-section, preterm labor, malpresentation, spontaneous abortion, and post-partum
hemorrhage than normally occurs in the general population, which in part might be due to
residual fibroids (32). On the other hand, Oman et al, who studied the long-term sequelae
of pelvic embolization for postpartum hemorrhage on fertility, found that all patients who
desired to get pregnant were able to do so and experienced uncomplicated deliveries in
the years after their embolization (33). Case series on pregnancy after myomectomy
report rates of premature delivery and other complications to be similar to rates for the
general population, however, the need for C-section necessarily increases if the uterine
cavity was substantially entered during myomectomy (34).
The increased interest in UAE as a minimally invasive treatment option for
fibroids has led to studies primarily assessing volume reduction and symptom relief.
Most have used ultrasound, and quality of life and sexual function have been less well
examined. For example, there have been case reports about sexual dysfunction after UAE
(35), but no published studies prospectively assessing the effect of UAE on sexual
function using validated measures. Therefore, the third aim of this research was to
reevaluate total uterine volume and largest fibroid volume, as well as fibroid-related
symptoms including quality of life and sexual function, after treatment with UAE using
quantitative MRI data and two validated instruments.
Finally, given that gynecologists have traditionally been the providers of
treatment for uterine fibroids (i.e., performing hysterectomy, myomectomy), the fourth
aim of this research was to investigate patients’ perceptions of their gynecologists’
opinion of UAE.
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Statement of purpose
In summary, the aim of this thesis was to test the following four hypotheses:
1.

There is a relationship between baseline MRI-determined uterine and fibroid size
and fibroid location within the uterus, and fibroid-related symptoms.

2.

Women with symptomatic uterine fibroids have worse quality of life and sexual
function than healthy women controls.

3.

Following treatment with UAE, uterine and fibroid size decrease, and fibroidrelated symptoms improve.

4.

More gynecologists are expressing a favorable opinion of UAE and are offering
UAE than two years earlier.

It is relevant to test these hypotheses given the prevalence of fibroids and the increasing
role of radiology in fibroid diagnosis and treatment. The practical benefit is that data
from this research will provide information for physicians and patients engaged in the
fibroid-treatment decision-making process.

METHODS

Study design and subjects
The patient sample, prospectively accrued, consisted of premenopausal women
undergoing UAE in the Department of Diagnostic Radiology, Vascular and
Interventional Radiology Division, at Yale-New Haven Hospital. Patients were self-
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referred or referred by gynecologists to the department for treatment. Exclusion criteria
for the study were malignancy and postmenopausal status. Eligibility was not restricted
by age, uterine or fibroid size, sexual orientation, or desire for fertility preservation. Onehundred and fifteen women had UAE performed by one of two hospital-based
Interventional Radiologists (Michael G. Tal, MD, and Jeffrey Poliak, MD) from June
2001 through December 2003, and all women were offered the opportunity to participate
in the study by either the Interventional Radiologist or his nurse practitioner. Fifty-two
(45%) of these women chose to participate and completed the questionnaire prior to
treatment with UAE. The same questionnaire was mailed (by the author) to these
participating women after treatment with UAE, and thirty-seven (71%) returned follow¬
up questionnaires one to six months after the procedure. Hospital review board approval
and patient informed consent were obtained.

Imaging
Following hospital UAE imaging protocol, women underwent pelvic MRI within
four weeks of UAE and six months post-procedure. MRI was performed in the
department utilizing a 1.5T scanner (General Electric, Signa, Milwaukee, WI) with a
pelvic phased array coil. Following a gradient echo localizer sequence, sagital STIR,
axial TI weighted SE, and axial and coronal FSE were obtained. Pre- and post¬
gadolinium scans were obtained in the sagital plane to assess for myoma enhancement.
The presence of submucosal fibroids, intramural fibroids with a submucosal component,
intramural fibroids, subserosal fibroids with an intramural component, and subserosal
fibroids were noted at baseline. Uterine dimensions were obtained from an axial image
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via electronic cursor measurements of the mid corpus width and AP dimensions, and
length was measured from a sagital image from the top of the fundus (or fundal myoma if
present) to the external os. Largest myoma diameter was obtained via cursor
measurement from axial and sagital images. Total uterine volume was calculated using
the equation for the volume of an ellipse |CC x AP x transverse x .52], and largest fibroid
volume was calculated using the equation for the volume of a sphere [4/3jc x (largest
myoma diameter/2)3]. MRI scans were read by residents and confirmed by attendings.
Volume calculations were double-checked by the author.

Questionnaires
Demographic and fibroid-related questionnaires were created by Dr. Tal and Robin
M. Masheb, PhD. In terms of demographic and clinical information, each patient was
asked about her age, race, education, marital status, employment, and primary reason for
seeking treatment. To assess fibroid-related symptoms, each patient was asked to rate the
frequency of urinary symptoms (frequency/urgency, incontinence), pain (pelvic,
abdominal, back), bleeding and bowel symptoms (constipation, diarrhea) that she
experienced in the month prior to the survey on a scale of 0 (not at all), 1 (about onefourth of the days in the past month), 2 (about one-half of the days in the past month), 3
(about three-fourths of the days in the past month) to 4 (every day in the past month).
In addition, each patient was asked to complete the following health-related quality of
life and sexual function instruments, respectively:
1.

Medical Outcomes Study Form Short-Form 36 (SF-36) Health Survey (1992)
(36): The SF-36 is a 36-item, state-of-the-art, self-report instrument to assess

12

health-related quality of life.

The SF-36 has well-established reliability and

validity, and was developed for use in the Medical Outcomes Study (37, 38). The
scale includes eight domains known to be most directly affected by disease and
treatment: physical functioning, social functioning, physical role limitation,
emotional role limitation, bodily pain, general health, mental health, and vitality.
SF-36 raw scale scores are transformed to t-scores (39). Higher scores reflect
better functioning for all subscales.
2.

Female Sexual Function Index (FSFI) (2000) (40): The 19-item FSFI has six
subscales — desire, arousal, lubrication, orgasm, satisfaction, and pain — as well
as an overall score. The questionnaire was developed as a multidimensional selfreport instrument for assessing the key domains of sexual function in women.
High test-retest reliability (r=0.79 to 0.86) and internal consistency (Cronbach’s
alpha values greater than and equal to 0.82), as well as construct and divergent
validity have been reported. Individuals are asked questions such as how difficult
it was to become lubricated (“wet”) during sexual activity or intercourse over the
past four weeks on a scale from extremely difficult, or impossible, to not difficult.
Higher scores reflect better sexual functioning.

Uterine artery embolization
Bilateral selective uterine artery catheterization was performed with the use of
fluoroscopic guidance. The catheter tips were placed within the transverse portion of the
uterine arteries. Bilateral angiography was performed in order to identify the arterial
anatomy and the branches feeding the fibroids. Five hundred to 710 micron polyvinyl
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alcohol particles were then injected into each uterine artery until stasis or near stasis was
achieved. Following embolization, a final arteriogram was obtained. Figure 1 shows preand post-embolization arteriograms for vasculature of a fibroid uterus. After the
procedure, each patient was admitted overnight to the Interventional Radiology service
for post-procedural pain management as needed.

Figure 1. a) Pre-embolization arteriogram of pelvic vasculature of a fibroid uterus, b)
Post-embolization arteriogram of pelvic vasculature of a fibroid uterus,
a)

b)

Telephone survey
In order to investigate trends in gynecologists’ opinions of UAE for fibroids, a
telephone study was initiated in August 1998 to assess patients’ perceptions of their
gynecologists’ opinion of the procedure. The surveys were administered to women
undergoing UAE as above from August 1998 to July 2000 (by Dr. Tal) and from July
2000 to April 2002 (by the author). Twenty-one patients completed the survey during
each time frame. Women were contacted chronologically, beginning with the first women
to have UAE in each of the respective time frames; participating women represent the
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first twenty-one women to be reached by telephone in each group. Each participant was
asked to rate her perception of her gynecologist’s initial opinion of UAE before the
procedure on a scale from 1 (strongly opposed) to 6 (very favorable) or 7 (unaware of the
procedure); whether the gynecologist offered UAE as a treatment option; whether she or
the gynecologist initiated discussion of UAE; and whether she continued to see the same
gynecologist after the procedure. In the second time frame, each participant was also
asked whether she had Internet access at home and whether she used the Internet to learn
about UAE.

Analysis
Data was analyzed using SPSS, version 10.0 (SPSS Inc, Chicago, IL) by the
author and Dr. Masheb. Frequency and percentages were calculated for categorical
variables, and means and standard deviations were calculated for continuous variables.
Pearson product moment correlation coefficients were used to examine relationships
among variables. Chi squares, t-tests, and ANOVAs were used the determine betweengroup differences.
Baseline quality of life and sexual function data were further analyzed using
effect sizes to compare the present sample with normative samples. Effect sizes were
determined by calculating the difference in scale scores between the UAE sample and the
control samples, and dividing by the average deviation of the two samples. Effect sizes
of 0.20, 0.50, and 0.80 or greater were considered small, medium, and large, respectively
(41), and student t tests were calculated to determine the significance of the effect sizes.
The control samples included a representative sample of the female general population
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from the validation studies of the SF-36 (39) and a representative sample of healthy
women from the original validation study of the FSF1 (40).
Data from the telephone survey assessing changing trends in gynecologists’
opinion of UAE were analyzed using Statcalc 1.1 (StatCalc Software, Etext.net publisher,
Venice, CA). Frequency and percentiles were calculated for categorical variables. All
reported p values were based on Fisher exact tests.

RESULTS

[N.B. The variation in N is a function of patients failing to answer all items on the
questionnaires, and MRls and MR1 reports missing from the hospital file room and
1DXRAD, the hospital computer radiology report system, respectively.]

Baseline Pre-UAE Data
The demographic and clinical characteristics of the participating women with
symptomatic fibroids seeking UAE are displayed in Table 1. The mean patient age was
45 years (range 33-56). The majority (54%) of women were Caucasian; 40% were
African-American, and 6% were Asian. Most women (59%) were highly educated, either
holding a four-year college degree or a graduate degree or professional training. Women
were more likely to be married or cohabiting or with a significant other (60%) than
divorced, separated, widowed, or never married (40%). Women were mostly working
full-time (78%), but 8% were unemployed.
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Patients were asked about their primary reason for seeking treatment for their
fibroids via a fill-in-the-blank question format. The majority of patients responded with
more than one reason. Responses were then coded by the author into the following six
categories: bleeding, pain, bulk, urinary, bowel symptoms, and dyspareunia. The most
common reasons patients reported were bleeding (53%) and pain (51%). In addition, 31%
self-reported bulk, 22% self-reported urinary symptoms, 4% self-reported bowel
symptoms, and 4% reported dyspareunia as the primary reason for seeking fibroid
treatment.

Table 1. Demographic and clinical characteristics of women with symptomatic fibroids seeking UAE
Age (N=52)
Total uterine volume (N=46)
Largest fibroid volume (N=46)

Race (N=52)
•
Caucasian
•
African American
•
Asian
Education (N=51)
•
Less than high school
graduate
•
High school graduate
•
Partial college or
specialized training
•
4-year college graduate
•
Graduate
degree/professional
training
Marital status (N=52)
•
Never married
•
Married or cohabiting
•
Significant other
•
Divorced/separates
•
Widowed
Employment status (N=49)
•
Working full-time (over
30 hrs/wk)
•
Working part-time (less
than 30 hrs/wk)
•
Unemployed
•
Student

Mean

SD

45.04
841.69 cc
347.80 cc

6.27
595.11 cc
352.47 cc

N

%

28
21
3

53.8
40.4
5.8

1

2.0

7
13

13.7
25.5

14
16

27.5
31.4

9
28
3
11
1

17.3
53.8
5.8
21.2
1.9

38

77.6

6

12.2

4
1

8.2
2.0
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Table 1 (continued)
Primary reasons for seeking
treatment (N=49)*
•
Urinary
•
Pain
•
Bleeding
•
Bowel
•
Bulk
•
Dyspareunia

22.4

11
25
26
2
15
2

51.0
53.1
4.1
30.6
4.1

* Note: Does not total to 100% because many women reported more than one primary reason for treatment.

The mean total uterine volume pre-UAE was 842 cc (range 91-2870 cc) and the
mean largest fibroid volume pre-UAE was 348 cc (range 1.44-1837.85 cc). Overall, 91%
of women had intramural fibroids, 54% had subserosal fibroids, 30% had submucosal
fibroids, 26% had intramural fibroids with a submucosal component, and 5% had
subserosal fibroids with an intramural component (Table 2). The majority of women
(74%) had fibroids in more than one location. Of the 26% with fibroids in one location,
the most frequent location was intramural (82%).

Table 2. Fibroid locations in women with symptomatic fibroids seeking UAE (N=43)
Present

Absent

Location

N

%

N

%

Intramural
Subserosal
Submucosal
Intramural with
submucosal
component
Subserosal with
intramural
component

39
23
13
11

90.7
53.5
30.2
25.6

4
20
30
32

9.3
46.5
69.8
74.4

2

4.7

41

95.3

In terms of fibroid-related symptoms (Table 3), most women reported urinary
frequency/urgency (81%), as well as pain (pelvic, abdominal, back) (81%) at least onefourth of the days or more in the month prior to the survey. In addition, 56% of women
reported bowel symptoms (constipation, diarrhea), and 33% reported bleeding at least
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one-fourth of the days or more in the month prior to the survey. Furthermore, 48% of
women reported urinary symptoms every day in the month prior to the survey.

Table 3. Frequency of Fibroid-related symptoms in women with symptomatic fibroids seeking UAE (N=52)

Symptoms Not at all

1/4 of days in 1/2 of days in 3/4 of days in
past month
past month
past month

Everyday in Totals: 1/4 of
past month
days or more

N

%

N

%

N

%

N

%

N

%

N

%

Urinary

10

19.2

8

15.4

6

11.5

3

5.8

25

48.1

42

80.8

Pain

10

19.2

15

28.8

9

17.3

9

17.3

9

17.3

42

80.8

Bleeding

35

67.3

6

11.5

5

9.6

2

3.8

4

7.7

17

32.7

Bowel

23

44.2

13

25.0

10

19.2

3

5.8

3

5.8

29

55.8

Table 4 contains the SF-36 means and standard deviations at baseline for the
cohort of women with symptomatic fibroids pre-UAE and for the representative sample
of the female general population from the validation studies of the SF-36 (39). In five of
the eight quality of life subscales — including physical role, bodily pain, general health,
vitality, and social functioning — the mean scores of women with symptomatic fibroids
were significantly different than the mean scores of the female general population at the
p<.05 level. In four of the five significant subscales, women with symptomatic fibroids
reported worse health-related quality of life than the female general population, with
effect sizes ranging from small to moderate.

However, in terms of the general health

subscale, women with fibroids reported better health-related quality of life than the
female general population.
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Table 4. Means, standard deviations, effect sizes, and paired t-tests for the SF-36 in women with
symptomatic fibroids and U.S. female norms*
Women with
fibroids (N=46)

U.S. female norms*
(N=1412)

SF-36

Mean

SD

Mean

SD

Physical
functioning
Physical role
Bodily pain

76.9

25.0

81.5

65.7
64.4

39.1
25.6

General
health
Vitality

80.0

Social
functioning
Emotional
role
Mental health

Effect size**
QualiTative
ns

t

P

24.6

Quanti¬
tative
-0.19

-1.24

ns

77.8
73.6

36.2
24.3

-0.32
-0.37

-2.07
-2.40

<. 025
<. 01

14.1

70.6

21.5

0.53

Small
Smallmoderate
Moderate

4.38

<. 005

48.3

25.3

58.4

21.5

-0.43

-2.68

<. 005

75.2

24.8

81.5

23.7

-0.26

Small
moderate
Small

-1.71

<. 05

74.8

38.1

79.5

34.4

-0.13

ns

-0.82

ns

69.6

20.0

73.3

18.7

-0.19

ns

-1.23

ns

* Sample from the National Survey of Functional Health Status (Ware et al., 1993) (39).
** Effect sizes of 0.20, 0.50, and 0.80 or greater are considered small, moderate and large, respectively
(Kazis et al., 1989) (41).
ns = not significant.
Higher scores reflect better health-related quality of life.

Table 5 contains the FSF1 means and standard deviations at baseline for the
cohort of women with symptomatic fibroids pre-UAE and for the representative sample
of healthy women from the original validation study of the FSF1 (40). In all sexual
function subscales - including desire, arousal, lubrication, orgasm, satisfaction and pain - and the overall score, the mean scores of women with symptomatic fibroids were
significantly different than the mean scores of healthy women controls at the p<.005
level. Women with symptomatic fibroids reported worse sexual function than healthy
women controls, with effect sizes ranging from small to moderate.
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Table 5. Means, standard deviations, effect sizes, and paired t-tests for the FSF1 in women with
symptomatic fibroids and healthy women without sexual dysfunction*
Women with
Fibroids
(N=:46)

Healthy women
w/o sexual dysfunction (N= 131)*

Effect size * *

FSFI

Mean

SD

Mean

SD

Quanti¬
tative

QualiTative

t

P

Desire
Arousal
Lubrication
Orgasm

5.7
12.6

-.54
-.64

7.5
5.4

-.58
-.39

-3.56
-4.39
-4.02
-2.60

Satisfaction

10.6

4.6

12.8

5.0

-.47

-3.11

<. 005

Pain
Overall score

10.1
24.1

5.3
9.5

13.9
30.5

6.2
10.7

-.66
-.63

Moderate
Moderate
Moderate
Smallmoderate
Smallmoderate
Moderate
Moderate

<. 005
<. 005

4.9

6.9
16.8
18.6
12.7

2.4
7.0

14.5
10.7

2.0
6.2
6.7

-4.60
-4.34

<. 005
<. 005

<. 005
<. 005

* Sample from Rosen et al., 2000 (40).
** Effect sizes of 0.20, 0.50, and 0.80 or greater are considered small, moderate and large, respectively
(Kazis et al., 1989) (41).
Higher scores reflect better sexual functioning.

Table 6 displays the correlations between the frequency of fibroid-related
symptoms and MRI-determined total uterine volume and largest fibroid volume at
baseline. Urinary frequency/urgency was significantly correlated with total uterine
volume and largest fibroid volume (r=.37, p=.01 and r=.35, p=.02, respectively), such
that greater frequency of urinary symptoms is related to larger uterine and fibroid
volumes.

Table 6. Correlations between fibroid-related symptoms and MRI-determined total uterine volume and
largest fibroid volume at baseline (N=46)
Total uterine volume
Symptoms

r

Urinary
Pain
Bleeding
Bowel

.37
-.28
-.13
-.19

P
.01*
.06
.40
.21

Largest fibroid volume
r
.35
-.28
-.27
-.28

P
.02*
.06
.07
.06

Table 7 displays the correlations between SF-36-determined quality of life and
MRI-determined total uterine volume and largest fibroid volume at baseline. Physical
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function and general health were significantly correlated with total uterine volume (p=
.04 in both cases respectively). Bodily pain was significantly correlated with largest
fibroid volume (p=.02).

Table 7. Correlations between SF-36-determined quality of life and MRl-determined total uterine volume
and largest fibroid volume at baseline (N=46)
Total uterine volume_Largest fibroid volume
SF-36 scales

r

Physical function
Physical role
Bodily pain
General health
Vitality
Social function
Emotional role
Mental health

.32
.08
.20
.31
.25
.21
-.07
.13

P
.04*
.63
.19
.04*
.11
.17
.66
.41

r
.25
.11
.35
.23
.29
.22
.06
.03

P
.11
.48
.02*
.15
.06
.15
.71
.84

Table 8 displays the correlations between FSFI-determined sexual function and
MRJ-determined total uterine volume and largest fibroid volume at baseline. None of the
FSFI scales - including desire, arousal, lubrication, orgasm, satisfaction, pain or overall
score - were significantly correlated with either total uterine volume or largest fibroid
volume.

Table 8. Correlations between FSFI-determined sexual function and MRl-determined total uterine volume
and largest fibroid volume at baseline (N=46)
Total uterine volume_Largest fibroid volume
FSFI scales

r

Desire
Arousal
Lubrication
Orgasm
Satisfaction
Pain
Overall score

.19
.04
-.02
-.02
.03
.05
.04

P
.23
.82
.89
.90
.87
.77
.81

r
.00
.03
-.12
-.01
.02
.07
.02

P
1.00
.83
.91
.95
.88
.65
.89

In order to investigate whether fibroid location had any effect on fibroid-related
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symptoms, ANOVAs were performed to test for between-group differences based on
presence or absence of fibroids in each of two locations. Subserosal and submucosal
fibroids were chosen because they provided relatively discrete, non-overlapping groups
(i.e., subserosal fibroids were present in roughly half the women (53%) and absent in
roughly half the women (47%); the groups with respect to submucosal fibroids were less
equal in size - 70% (present) and 30% (absent); analysis was not run on intramural
fibroids because the two groups - those with intramural fibroids present (91%) and those
with submucosal fibroids absent (9%) - because of insufficient power). No significant
differences with respect to fibroid-related symptoms were found between patients with
and patients without subserosal fibroids (Table 9).

Table 9. Comparison of fibroid-related symptoms in patients with and without subserosal fibroids (SSF)
using ANOVA
Presence of SSF (N-23)Absence of SSF (N=20)
Urinary
Pain
Bleeding
Bowel

Mean

SD

Mean

SD

F

2.43
1.65
.61
.74

1.73
1.34
1.12
1.10

2.25
1.75
.70
1.15

1.74
1.41
1.30
1.35

.12
.06
.06
1.21

P
.73
.82
.81
.28

No significant differences with respect to fibroid-related symptoms were found between
patients with and patients without submucosal fibroids (Table 10).

Table 10. Comparison of fibroid-related symptoms in patients with and without submucosal fibroids (SMF)
using ANOVA
Presence of SMF (N=13)Absence of SMF (N=30)
Urinary
Pain
Bleeding
Bowel

Mean

SD

Mean

SD

F

2.23
1.38
.85
.92

1.64
1.26
1.34
1.19

2.40
1.83
.57
.93

1.77
1.39
1.14
1.26

.09
1.00
.49
.00

P
.78
.32
.49
.98
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Post-UAE Data
Thirty-seven patients (71%) completed follow-up questionnaires between one and
six months post UAE. The questionnaires were identical to the baseline questionnaires.
The baseline and follow-up groups were not significantly different with respect to age
(F(1,X)=.85, p=.36), race [X2(l)=0.97, p=.32], education [X2( 1 )= 1.01, p=.32], or
employment [X2(1)=0.18, p=.67], The baseline and follow-up groups differed with
respect to marital status [X2( 1)—5.11, p=.02], such that significantly more married or
cohabiting women participated in the follow-up than did in the baseline survey.
Seventeen patients (37%) of the baseline sample for which MRI data was
available (N=46) have completed follow-up MRIs six months post UAE as this thesis
goes to print. Total uterine and largest fibroid mean volumes at baseline and at six
months post-UAE are displayed in Table 11, with p values based on t-tests. Mean total
uterine volume six months post-UAE was 493 cc (range, 100-1304 cc), with a 41%
volume reduction from baseline. Mean largest fibroid volume six months post-UAE was
228 cc (range 2-1150 cc), with a 35% volume reduction from baseline.

Table 11. Means, standard deviations, and paired t-tests for total uterine volume and largest fibroid volume
at baseline and six months after-UAE
Baseline (N=46)

Total uterine
volume
Largest
fibroid
volume

6 months post-UAE (N=17)
t

492.95

SD
366.27

2.73

P
.02*

227.54

274.48

2.46

.03*

Mean

SD

Mean

841.69

595.11

347.80

352.47

In terms of frequency of fibroid-related symptoms post-UAE (Table 12), 49% of
women reported no urinary frequency/urgency, 54% reported no pain, 70% reported no
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bleeding difficulties, and 50% reported no bowel problems in the month prior to survey.
Furthermore, patients reported significantly less urinary frequency/urgency post-UAE
than at pretreatment (F(l,36=16.59, p<.001), with a 54% decrease in urinary symptoms
(Table 13). Patients also reported significantly less pain post-UAE than at pretreatment
(F(l,36)=9.37, p=.003), with a 49% decrease in pain symptoms.

Table 12. Frequency of fibroid-related symptoms after UAE (N=37)

Symptoms Not at all
Urinary
Pain
Bleeding
Bowel

1/4 of days in
past month

1/2 of days in
past month

3/4 of days in
past month

Everyday in
past month

Totals: 1/4 of
days or more

N

%

N

%

N

%

N

%

N

%

N

%

18
20
26
18

48.6
54.1
70.3
50.0

6
8
8
12

16.2
21.6
21.6
33.3

6
4
2
2

16.2
10.8
5.4
5.6

4
1
0
3

10.8
2.7
0
8.3

3
4
1
1

8.1
10.8
2.7
2.8

19
17
11
19

51.4
45.9
29.7
51.4

Table 13. Univariate analysis of fibroid-related symptoms before and after UAE
Pre-UAE (N==52)

Post-UAE (N==37)

Symptom

Mean

SD

Mean

SD

F

Urinary
Pain
Bleeding
Bowel

2.48
1.85
.73
1.04

1.65
1.39
1.25
1.19

1.14

1.36
1.33
.83
1.06

16.59
9.37
1.59
.89

.95
.43
.81

P
.000*
.003*
.211
.348

Higher scores reflect worse symptoms (Symptoms scale: 4 = experienced the given symptom every single
day in the month prior to survey; 3 = experienced the given symptom three-fourths of days in the month
prior to survey; 2 = experienced the given symptom half the days in the month prior to survey; 1 =
experienced the given symptom one-fourth of the days in the month prior to survey; 0 = did not
experienced the given symptom at all in the month prior to survey)

In terms of quality of life, women reported significantly better physical function
post-UAE than at pretreatment (F(l,36)=8.11, p=.005), with a 22% improvement in
physical function (Table 14). Women also reported significantly better quality of life with
respect to bodily pain post-UAE than at pretreatment (F( 1,36)=10.07, p=.002), with a
26% improvement in bodily pain. The physical component summary scores of the SF-36
were also higher post-UAE than at pretreatment (F(l,36)=8.13, p=.006), with a 13%
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improvement (with higher scores reflecting better quality of life).

Table 14. Univariate analysis of SF-36-determined quality of life before and after UAE
Pre-UAE (N=52)Post-UAE (N=37)
SF-36 scales

Mean

SD

Mean

SD

F

Physical
function
Role
physical
Bodily pain
General
health
Vitality
Social
function
Role
emotional
Mental
health
Physical
component
summary
score
Mental
component
summary
score

77.4

26.0

94.2

28.6

8.11

P
.005*

66.8

38.2

77.0

31.9

1.76

.188

64.2
80.1

25.0
14.1

80.6
82.3

22.6
16.5

10.07
.43

.002*
.516

49.1
76.4

24.6
24.1

53.9
84.4

23.3
19.9

.81
2.68

.370
.106

78.0

36.6

84.7

32.0

.81

.370

70.9

19.7

74.1

16.2

.60

.440

47.19

9.34

53.24

9.36

8.13

.006*

47.94

10.41

48.83

9.20

.16

.70

Higher scores reflect better quality of life.

Post UAE, women's reported sexual function was not significantly different than
at pretreatment in any respect, including desire, arousal, lubrication, orgasm, satisfaction,
pain, or the overall score.

Table 15. Univariate analysis of FSFI-determined sexual function before and after
Pre-UAE (N=52)

Post-UAE (N=37)

FSFI scales

Mean

SD

Mean

SD

F

Desire
Arousal
Lubrication
Orgasm
Satisfaction
Pain
Overall
Score

5.67

1.87
6.11
6.70
4.95
4.41
5.19
9.38

5.97
10.67
11.27
8.34
9.10
8.15
20.45

2.05
7.61
8.95
6.29
5.54
6.87
12.67

.48
1.53
3.46
2.90
1.28
1.63
1.81

12.51
14.44
10.45
10.37
9.83
23.75

Higher scores reflect better sexual function.

P
.492
.220
.066
.092
.262
.205
.182
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Changing Trends in Gynecologists’ Opinions of UAE
Table 16 contains the results of the telephone surveys administered during the two
time frames. The two survey groups were quite similar. The mean patient ages were 45
years in the first survey time frame and 44 years in the second. Seventy-five percent of
respondents to the first survey and 73% of respondents to the second survey had earned at
least a 4-year college degree (differences not statistically significant, Fisher exact test,
p>.05).
According to patients’ perceptions, there was a significant difference in the
number of gynecologists initially opposed to UAE (pc.05), with fewer gynecologists
initially opposed to UAE in the second survey in comparison with the first. There was
also a significant difference in the number of gynecologists who offered UAE as a
treatment option (pc.05), with more gynecologists offering UAE as a treatment option in
the second survey in comparison with the first. In addition, as reported by patients, there
was a significant difference in the number of gynecologists who initiated discussion of
UAE with their patients in the second survey in comparison with the first. Finally, there
was no significant difference in the percentage of patients who did not return to
gynecologists perceived by their patients to be initially opposed to UAE when comparing
the two surveys.
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Table 16: Changing trends in patients’ perceptions of gynecologists’ opinions of UAE: telephone survey
results
Time Period
August 1998 to July 2000_July 2000 to April 2002
Frequency

Percent

Frequency

Percent

No. of
respondents

21/50

42%

21/39

54%

Gynecologists
initially
opposed to
UAE

16/21

76%

7/21

33%

<.05

Gynecologists
who offered
UAE as a
option

1/21

5%

8/21

38%

<.05

Gynecologists
who initiated
discussion of
UAE

2/21

10%

9/21

43%

<.05

Patients who
didn’t return to
gynecologists
initially
opposed to
UAE

8/9

89%

5/7

71%

Ns

P

Ns = not significant

Participants in the second survey were also queried regarding availability of
Internet at home and whether they used it to learn about UAE. Seventy-one percent
(15/21) reported they had Internet access at home, and 62% (13/21) reported that they
used the Internet to learn about UAE.

DISCUSSION

The purpose of this research was to use quantitative MRI data and validated
instruments to establish baseline radiological, physiological and psychosocial
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characteristics of premenopausal women with symptomatic uterine fibroids and to follow
these variables after treatment with UAE. This research represents the largest systematic
examination of patients undergoing uterine artery embolization for fibroids to date at
Yale-New Haven Hospital, Department of Diagnostic Radiology, Vascular and
Interventional Radiology Division. The design of the research has several strengths. First,
we used MRI to characterize the relationship between uterine and fibroid size and fibroid
position within the uterus, and fibroid-related symptoms, including quality of life and
sexual function, which has not been done previously. Second, in terms of quality of life
and sexual function, we used two empirically validated and reliable questionnaires, the
SF-36 and the FSFI, to report baseline characteristics of women with symptomatic
fibroids seeking UAE and compared them to controls to understand these women relative
to norms.

Baseline Data
The first hypothesis of this study was that there is a relationship between baseline
uterine and fibroid size and fibroid position within the uterus, and baseline fibroid-related
symptoms - and we sought to define more specifically the nature of this relationship. We
also hypothesized that women with symptomatic uterine fibroids have worse quality of
life and sexual function than healthy women controls - and we sought to define more
specifically the severity of the dysfunction.
The baseline characteristics of the women participating in our study are similar to
the results of the largest multi-center prospective UAE study ever to be performed (Pron
et ai. 555 Canadian women undergoing UAE at eight Ontario university and community
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hospitals) (42). Our cohort (54% Caucasian, 40% African American, 6% Asian) had an
average age of 45, similar to the Pron et al cohort (66% Caucasian, 23% black, 11%
Asian) which had a average age of 43. The only respect in which our cohort was
considerably different at baseline was with respect to pre-UAE uterine and largest fibroid
volumes: our cohort had a larger pre-UAE mean total uterine volume (842 cc, versus 704
cc in the Pron et al cohort) and a larger pre-UAE mean largest fibroid volume (348 cc,
versus 308 cc in the Pron et al cohort).
In terms of women’s primary reason for seeking treatment, we found that the most
common reasons were bleeding (53%), pain (51%), bulk symptoms (31%), urinary
symptoms (22%), bowel symptoms (4%), and dyspareunia (4%). This information on
self-reported reasons for seeking treatment is interesting in conjunction with our findings
about sexual function: while only 4% of our cohort self-reported pain with sexual
activity, when prompted with multiple-choice questions, the same cohort was found to
have worse sexual function on every single scale of the FSFI — including pain — than
healthy controls. A number of possibilities may explain this discrepancy, including: that
women are not seeking interventional treatment for fibroids because of sexual
dysfunction; that women do not think of fibroids as a possible cause of their sexual
dysfunction; that women are not bothered by their sexual dysfunction; or, that women are
bothered by their sexual dysfunction but are not raising the issue with their physicians.
Thus, one practical benefit of our study is that it provides evidence in support of
physicians asking women with fibroids about their sexual health.
In terms of frequency and percent of symptoms, we found that 81% of women
reported urinary symptoms at least one-fourth of the days or more in the month prior to
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the survey. This is similar to the Pron et al UFE trial in which 73% of patients reported
urinary urgency/frequency at baseline (42). With respect to bleeding, 37% of our cohort
reported bleeding symptoms at least one fourth of the days or more in the month prior to
survey. This is also similar to the Pron et al UFE trial, in which 31% of the women
reported lengthy, i.e., longer than seven days, menstrual periods.
In terms of quality of life, we found that women seeking UAE for symptomatic
fibroids reported minimally to moderately worse health-related quality of life with
respect to physical role, bodily pain, vitality, and social functioning on the SF-36 than the
general female population. These findings extend the work by Spies et al, who adapted
the SF-36 for women with uterine fibroids, but found small-to-moderate correlations
between his fibroid-specific HRQOL measure and the SF-36 when validating his
instrument (12). Our confirmation utilizing the SF-36, a widely used measure of health
related quality of life, that women seeking UAE for symptomatic fibroids had worse
health-related quality of life than healthy women is striking given the prevalence of the
condition in women of reproductive age. We did, however, find that our cohort of women
with fibroids had better quality of life with respect to general health than the general
female population, which may reflect the fact that our cohort with fibroids was largely
healthy women without other comorbidities.
In terms of sexual function, we found that women seeking UAE for symptomatic
fibroids reported worse sexual function in all areas — including desire, arousal,
lubrication, orgasm, satisfaction and pain — and on the full scale score than healthy
women controls. This is consistent with a recent population-based cross-sectional study
by Lippman et al who found that women with fibroids were more likely to report
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moderate or severe dyspareunia than women without fibroids (43). Spies et al also
reported that women with fibroids had worse sexual function than normal controls, but
this conclusion was drawn from answers to a limited number (two) of questions (“During
the previous three months, how often have your symptoms related to uterine fibroids
diminished your sexual desire? Caused you to avoid sexual relations?”) (12). Thus, our
confirmation with the FSF1, an empirically validated 19-item measure of female sexual
function, that women with symptomatic fibroids have worse sexual function than healthy
women controls both replicates and extends the work of Spies et al.
We found that urinary symptoms were related to larger uterine and fibroid size.
This is particularly relevant given that the present study also found that 81% of women
reported urinary symptoms at least one fourth of the days or more in the month prior to
survey. This is an important finding that needs to be followed up with treatment-outcome
research to examine whether decrease in uterine and fibroid size post-UAE decreases
urinary as well as other fibroid-related symptoms as well, something our post-UAE data
only preliminarily begins to investigate. However, in terms of pretreatment data, to our
knowledge, no published studies exist examining the correlation between baseline uterine
and fibroid size, and fibroid-related symptoms other than bleeding, including quality of
life and sexual function.
In terms of quality of life, we found that three aspects of quality of life including physical function, general health, and bodily pain - were significantly
correlated with either total uterine volume or largest fibroid volume. The fact that the
bodily pain scale of the SF-36 was significantly correlated with largest fibroid volume is
consonant with our finding that pain as a fibroid-related symptoms was significantly
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correlated with total uterine volume, given that total uterine volume is a function of
largest fibroid volume plus volume contributed by other fibroids, if present. These
findings suggest that pain is in some way related to larger volume, potentially because of
compression from mass effect. The fact that physical function and general health were
also correlated with total uterine volume implies that beyond individual symptoms,
fibroids may impact to some degree on overall quality of life depending on the size of the
uterus. However, the majority of quality of life subscales were not correlated with total
uterine volume or largest fibroid volume. These results are consistent with Pron et al,
who asked women to rate the overall impact or interference of fibroids on their daily lives
on a scale from one (little or minimal interference) to ten (total or complete interference
with their daily or usual activities), and found that uterine and fibroid size were not
responsible for high “life impact” scores in some cohorts (42).
No aspects of sexual function, including pain, were significantly correlated with
either MRI-determined total uterine volume or largest fibroid volume, despite the fact
that our cohort of women with fibroids was found to have worse sexual function on every
FSFI scale than healthy women controls. Lippman et al also reported that total volume of
fibroids was not related to dyspareunia using different assessment methods (i.e.,
ultrasound-generated volume data and a visual analog scale) (43). Thus, our confirmation
with MRI and the validated FSFI that pain with respect to sexual function is not
correlated with volume in women with symptomatic fibroids seeking UAE both
replicates and extends the work of Lippman et al, who studied a non-care-seeking
population. This emphasizes that physicians should routinely asking women with fibroids
about their sexual function, irrespective of uterine or largest fibroid size. More research is
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needed to better understand what may account for differences in sexual function between
women with fibroids and women without fibroids (e.g., fibroid neovascularization).
With respect to fibroid location, our results are consonant with the literature: for
example, our rate of submucosal fibroids (30%) was similar to that found by Kjerulff et
al (27% overall) in their pathological analysis of hysterectomy specimens (44). In terms

of the potential relationship between fibroid location and symptoms, our results do not
support the contention of some that fibroids located submucosally contribute
disproportionately to heavy bleeding than fibroids in other locations (7). In contrast, we
found that the presence of submucosal fibroids did not appear to have a significant effect
on any fibroid-related symptoms, including bleeding. This is consistent with recent work
by Wegienka et al who found that nonsubmucosal fibroids were associated with heavy
bleeding to the same extent as submucosal fibroids (6). Our results also do not support
the literature that subserosal fibroids contribute disproportionately to pressure and pain.
In contrast, we found that the presence of subserosal fibroids did not appear to have a
significant effect on any fibroid-related symptoms, including pain. Although our analysis
was limited by small sample size, and non-equal groups potentially confounded by the
presence of fibroids in other locations, our findings suggest that in contrast to
endometriosis in which the anatomic location of endometriosis does effect pelvic pain
symptoms (9), the anatomic location of fibroids - specifically those located subserosally
or submucosally -- does not appear to be related to fibroid-related symptoms.
Our study of the impact of MRI-determined uterine and fibroid size and fibroid
position on fibroid-related symptoms, including quality of life and sexual function, adds a
new dimension to the existing body of literature: although abdominal and transvaginal
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ultrasound have been used in attempting to characterize the relationship between bleeding
symptoms and fibroid size and location (6), we are unaware of any published studies that
utilize MRI to measure the size and location of fibroids while investigating such
relationships. Dueholm et al found that the mean number of correctly identified myomas
was significantly higher by magnetic resonance imaging than by transvaginal ultrasound
(45).

Post-UAE Data
The third hypothesis of this research was that uterine and fibroid size would
significantly decrease after treatment with UAE, and that fibroid-related symptoms would
improve. However, the small sample size at follow-up post-UAE (37/52=71% for
questionnaires, 17/46=37% for MRIs) and the possibility of reporting bias among these
patients limits the reliability of conclusions generated from the data. Results in this arm
of the research must be considered as preliminary/pilot data only, guiding future research.
While uterine and largest fibroid volume reductions were 35% and 42%
respectively three months after UAE in the Pron et al UFE Trial (46) and 34% and 50%
respectively 4.4 months after UAE in a trial by Spies et al (48), we found a 41%
reduction in uterine volume and 35% reduction in largest fibroid volume from pre- to
post-UAE (Figure 2). Thus, despite the limitations of our data, our volume reductions
were consistent with the literature.
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In terms of symptom relief, our preliminary data revealed that the most substantial
improvements were in urinary and pain symptoms, with the frequency of both nearly
halving from baseline to follow-up: 81% of patients pre-UAE versus 49% of patients
post-UAE reported urinary frequency/urgency at least one fourth of days per month; 81%
of patients pre-UAE versus 46% of patients post-UAE reported pain at least one fourth or
days per month). It would be important for future research to focus on investigating
whether change in uterine and fibroid volume correlates with changes in fibroid-related
symptoms. This is of particular interest given findings by de Souza et al that volume
reduction did not correlate with improvement in fibroid-related symptoms (47), by Pron
et al that improvements in menorrhagia were unrelated to post-UAE volume reduction

(46), and by Spies et al that the odds of improved bulk-related symptoms were not
associated with fibroid-volume change (48).
Post UAE, we found that quality of life scores improved in all SF-36 scales, with
a statistically significant improvement in the subscales of physical function and bodily
pain. Although only preliminary data, significant improvements in these two areas is
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important, given that both were correlated with volume measurements pretreatment (i.e.,
physical function correlated with total uterine volume, p=.04; bodily pain correlated with
largest fibroid volume, p=.02). This begs the question of whether post-treatment
improvement in symptoms, including quality of life, correlate with post-treatment
improvement (i.e., decrease) in uterine and fibroid size, although recent results from de
Souza et al, Pron et al, and Spies et al detailed above suggest that this may not be the
case.
Preliminary results with respect to post-UAE quality of life were consistent with
the limited literature in this area: Spies et al also found that health-related quality of life
scores improved at all instances at follow-up post-UAE (48). Our confirmation with the
SF-36, a widely used measure of health related quality of life, that women reported
improved health-related quality of life after UAE both replicates and extends the work of
Spies et al, albeit with a smaller sample size. Our findings in this area are also important
given mixed reports in the literature about quality of life after hysterectomy, although few
(six total, two relevant, based on a PubMed search of “hysterectomy” and “SF-36”)
utilize the SF-36 as we do. While Lambden et al report that women undergoing
hysterectomy for nononcologic reasons had improved health status and psychological
well-being as measured by the SF-36 in the initial period after surgery (49), in contrast,
Byles et al reported that women who had had hysterectomy had significantly poorer
physical and mental health as measured by the SF-36 quality of life profile than women
who had not had hysterectomy (50).
Post UAE, we found no significant change in sexual function in comparison with
pretreatment. On the one hand, it may be disappointing that there was not an
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improvement in sexual function given our finding that women with fibroids have
significantly worse sexual function than normal controls. On the other hand, the results
are encouraging in light of previous case reports about sexual dysfunction after UAE
(35). It is also important given recent reports in the literature about sexual dysfunction
after hysterectomy. Roovers et al reported that the prevalence of one or more bothersome
sexual problems after vaginal hysterectomy, subtotal abdominal hysterectomy, and total
abdominal hysterectomy was 43%, 41% and 39%, respectively (51). Additionally, in
another study comparing total laparoscopic hysterectomy and laparascopically assisted
vaginal hysterectomy. Long et al found a significant reduction in the frequency of
orgasms after surgery in both groups (p<.05) (52). These newer studies stand in contrast
to previous reports by Weber et al, who reported no change in sexual functioning after
abdominal hysterectomy (53), and by Rhodes et al, who reported that sexual functioning
improved overall after hysterectomy, with the frequency of sexual activity increasing and
problems with sexual functioning (e.g., dyspareunia, inorgasmia, low libido) decreasing
(54).
Exactly how hysterectomy could cause sexual dysfunction is not clear; both
abstract and anatomically-based theories have been proposed. First, as Roovers et al
write, “historically the uterus has been regarded as the regulator and controller of
important physiological functions, a sexual organ, a source of energy and vitality, and a
maintainer of youth and attractiveness. Women are concerned that hysterectomy may
affect their sexual wellbeing or their sexual attractiveness” (51). Second, the pelvic
autonomic nerve plexus may be damaged during hysterectomy in several ways: during
division of the cardinal ligaments, the main branches of the nerve plexus that pass under
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the uterine arteries may be damaged; cervical removal may result in the loss of a large
part of the nerve plexus; or if a radical hysterectomy is being performed, the major part of
the vesical innervation may be damaged during blunt dissection of the bladder from the
uterus and cervix (56, 57). In contrast, UAE avoids the surgical disruption of pelvic nerve
plexi intimately involved in female sexual response and pleasure.

Changing trends in gynecologists’ opinion of UAE
Overtime, we observed that a greater proportion of our UAE patients seemed to
be referred by gynecologists, rather than self-referred, and therefore the fourth hypothesis
of our research was that more gynecologists had a favorable opinion of UAE and were
offering UAE in comparison to two years earlier. Our telephone survey confirmed this
hypothesis, revealing a trend of increasing acceptance by gynecologists of UAE for
fibroids, as perceived by their patients. This research extends the literature in this area by
providing an examination of gynecologists’ changing opinion of UAE over time, albeit
an indirect one. Since UAE is a relatively new treatment for uterine fibroids, and since
gynecologists are most often the primary physicians who counsel patients about treatment
options, their knowledge, attitude and acceptance of UAE as a treatment modality is of
critical importance.
Based on patients’ reports of their gynecologists, the following specific trends
were noted: fewer gynecologists appeared to be initially opposed to UAE in the second
survey (33%) than in the first (76%); a greater number of gynecologists offered UAE as a
treatment option in the second survey (38%) than in the first (5%); and a greater number
of gynecologists initiated discussion of UAE with their patients in the second survey
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(43%) than in the first (10%). However, despite these significant gains, according to
patients’ reports, 62% of gynecologists still did not offer UAE as a treatment option for
fibroids. This is disconcerting, since informed consent dictates discussion of all treatment
options available.
Although there appears to be an overall increasing acceptance of UAE by
gynecologists, there was no significant difference in the percentage of patients who did
not return to gynecologists perceived by their patients to be initially opposed to UAE
when comparing the first and second surveys. It may well be that gynecologists who fail
to discuss UAE or communicate a negative attitude towards the procedure may risk
losing their patients.
Seventy-one percent of women in the second survey group had Internet access at
home, and 62% used the Internet to learn about UAE. Thus, if gynecologists do not
discuss UAE as a treatment option, it appears that many patients will learn about the
procedure through the Internet themselves. Physician-conveyed information would
I

promote a healthier doctor-patient relationship, as well as counter misinformation
contained within unregulated Internet sites.
I

Limitations
There are several limitations to our research.

First, the study was limited to

women with fibroids who were symptomatic and seeking interventional treatment.
Therefore, our results do not necessarily apply to women with fibroids who are
asymptomatic or symptomatic but seeking non-interventional treatment (i.e., medical
treatment, myomectomy, hysterectomy).

:

Second, our SF-36 quality of life and FSFI
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sexual function analyses used historical controls collected by other investigators, and
therefore were unable to control for potential confounders such as the presence of
fibroids in women in the control groups. Third, the fact that patients could have had
other health issues that potentially could have caused pain or urinary symptoms (e.g.,
chronic interstitial cystitis), pressure (e.g., benign ovarian cyst), or bowel symptoms (e.g.,
inflammatory bowel disease), was not controlled for in our analyses. Fourth, we note the
possibility of reporting bias: some of the patients who underwent UAE left items blank
on the questionnaire or did not answer the questionnaire at all at follow-up; they might
have experienced detrimental effects which were not included in analyses. Furthermore, a
large number of women who completed follow-up questionnaires had not yet reached the
time, or failed to return, for the six month post-UAE MRI and therefore were also not
included in analyses. Fifth, our follow-up questionnaire data was accrued between one
and six months after UAE, instead of at one specific time point. Sixth, we note our small
sample size.
In terms of the telephone survey, there were several limitations as well. First, the
study was limited to women’s perceptions of their gynecologists’ opinion of UAE.
Therefore, while patients’ perceptions of gynecologists’ opinion of the procedure are
important in that they may impact whether a patient stays with the same gynecologist, the
results of this study do not necessarily reflect gynecologists’ actual opinion of the
procedure. Second, the study was limited to surveying women undergoing UAE at one
specific practice site, and therefore may reflect locally but not necessarily nationally
changing trends in gynecologists’ opinion of UAE.

41

CONCLUSIONS
In summary, in this largely prospective multi-disciplinary study, we examined
radiological, physiological and psychosocial variables in premenopausal women with
symptomatic uterine fibroids before and after uterine artery embolization.
We hypothesized about the relationship between baseline uterine and fibroid size
and fibroid position, and baseline fibroid-related symptoms. We found that MRIdetermined uterine and largest fibroid size, but not fibroid position, appear to effect
urinary symptoms and some aspects of quality of life, but not sexual function. We also
hypothesized that women with symptomatic uterine fibroids have impaired quality of life
and sexual function. In addition to urinary, pain, bleeding and bowel symptoms, we
found that women with symptomatic fibroids had worse quality of life and sexual
function than healthy controls. Based on these findings, it is recommended that health
care providers treating women with uterine fibroids specifically ask about quality of life
and sexual function, because women may be unaware of their impaired function or may
not raise the issue themselves.
Post-UAE, we hypothesized that there would be a decrease in uterine and fibroid
size, and an improvement in fibroid-related symptoms. We found that uterine and fibroid
volume decreased significantly, and that their were significant improvements in urinary
and pain symptoms, as well as some aspects of quality of life. Future research tracking
fibroid-related symptoms, including quality of life and sexual function should be
performed in a consistent manner before and after a variety of treatment modalities, in
order to establish evidence-based treatment guidelines.
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In view of our telephone survey results that more gynecologists had a favorable
opinion of UAE and were offering UAE currently in comparison to two years previously,
it is recommended that Interventional Radiologists treating women with UAE continue to
work actively to create a positive relationship with gynecologists, involving the referring
MD before, during and after the UAE procedure, in order to enhance the acceptance of
this safe, effective procedure.
In conclusion, our research illustrates that women with symptomatic leiomyomata
seeking UAE are burdened with troublesome fibroid-related symptoms and impaired
quality of life and sexual function. UAE, increasingly accepted by gynecologists, reduces
uterine and fibroid volume and provides improvement in fibroid-related symptoms,
including some aspects of quality of life, without worsening sexual function. Continued
multidisciplinary research such as this involving radiologists, gynecologists and
psychologists has the potential to greatly assist physicians and patients alike to make
more informed decisions about the treatment of this highly prevalent women’s health
condition.
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Changing Trends in Gynecologists' Opinions of
Uterine Artery Embolization for Fibroids: The
Patient's Perspective
Elizabeth Kagan Arleo, BA, Jeffrey Poliak, MD, and Michael G. Tal, MD
This study's purpose was to survey patients' perceptions of gynecologists' opinions of uterine artery embolization
(UAE) for fibroids. Twenty-one women who underwent UAE between July 2000 and April 2002 and 21 women who
underwent UAE between September 1998 and July 2000 completed questionnaires. Each woman was asked what her
gynecologist's initial opinion was toward UAE, what treatment options were offered, who initiated discussion of UAE,
and whether she returned to the same gynecologist after UAE. As of 2002, more gynecologists had a favorable opinion
of UAE and were offering UAE versus in the year 2000. The majority of patients whose gynecologists initially opposed
UAE did not return to the same gynecologists, reflecting a similar trend noted 2 years earlier.
J Vase Interv Radiol 2003; 14:1559-1561
Abbreviation:

UAE = uterine artery embolization

GIVEN that gynecologists have tradi¬
tionally been the providers of treat¬
ment for uterine fibroids, the purpose
of this article is to investigate gyne¬
cologists' opinion of uterine artery em¬
bolization (UAE), a relatively new
treatment option provided by inter¬
ventional radiologists. Uterine fi¬
broids, also known as leiomyomata,
affect 30%-40% of women of repro¬
ductive age in the United States (1).
Fibroids are symptomatic in 35%-50%
of women who have them, causing
menorrhagia, pressure-related symp¬
toms (bloating, urinary frequency or
retention, constipation), pain (dys¬
menorrhea, dyspareunia), and repro¬
ductive difficulties (infertility, miscar¬
riage). Medical treatment options for
symptomatic fibroids include gonado-
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tropin-releasing hormone analogues
(2) and, more recently, danazol and
gestrinone (3), whereas surgical treat¬
ment options include hysterectomy
and myomectomy. More recently,
UAE, a minimally invasive alternative
therapy performed by interventional
radiologists, has been used as a pri¬
mary treatment for symptomatic uter¬
ine fibroids. Hysterectomy is currently
the most common surgical treatment
for women with uterine fibroids, and
fibroids are the number-one indication
for performing hysterectomy: 40% of
the estimated 600,000 hysterectomies
performed annually in the United
States are performed for fibroids (4).
UAE for fibroids, first described by
Ravina et al in 1995 (5), has been gain¬
ing popularity for several reasons: the
procedure is minimally invasive with
little blood loss, is associated with less
morbidity, requires shorter hospital¬
ization during recovery, and allows
for preservation of the uterus (6-13).
However, the American College of
Obstetricians and Gynecologists Prac¬
tice Bulletin, which provides clinical
management guidelines for obstetri¬
cians and gynecologists, states that
"uterine artery embolization is re¬
garded as investigational" (14). How¬
ever, anecdotal evidence suggests that

gynecologists' opinions may be chang¬
ing over time as more women seek
uterine-preserving
treatments
for
symptomatic fibroids.
Given the prevalence of fibroids,
the increasing role of UAE in treating
them, and the lack of data examining
gynecologists' opinion of the proce¬
dure, the aims of the present study
were to survey patients' perceptions of
their gynecologists' expressed opin¬
ions of UAE and to compare these re¬
sults to those of the same survey con¬
ducted 2 years earlier.

MATERIALS AND METHODS
In August 1998, a telephone study
was initiated to assess patients' per¬
spective of their gynecologists' opin¬
ion of UAE and to examine changing
trends, if any. The surveys were ad¬
ministered during two time frames:
from August 1998 to July 2000 and
from July 2000 to April 2002. Twentyone patients completed the survey
during each time frame.
For entry into the study, patients
were required to have undergone
UAE for symptomatic uterine fibroids
at the practice site and be participating
in another survey regarding UAE con¬
ducted by the same principal investi-
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Telephone Survey Results

Time Period

No. of respondents
Gynecologists initially
opposed or strongly
opposed to UAE
Gynecologists who offered
UAE as a treatment option
Gynecologists who initiated
discussion of UAE with
their patients
Patients who did not return to
gynecologists who were
initially opposed to UAE

August 1998 to
July 2000

July 2000 to
April 2002

P Value

21/50 (42)
16/21 (76)

21/39 (54)
7/21 (33)

<.05

1/21 (5)

8/21 (38)

<.05

2/21 (10)

9/21 (43)

<.05

8/9(89)

5/7(71)

NS

Note.—Values in parentheses are percentages.

gators. Patients were self-referred or
referred by gynecologists for treat¬
ment. Exclusion criteria were malig¬
nancy and postmenopausal status.
Each participant was asked to rate
her gynecologist's initial opinion of
UAE before the procedure on a scale
from 1 (strongly opposed) to 6 (very
favorable) or 7 (unaware of the proce¬
dure); whether the gynecologist of¬
fered UAE as a treatment option;
whether she or the gynecologist initi¬
ated discussion of UAE; and whether
she continued to see the same gynecol¬
ogist after the procedure. In the sec¬
ond survey, each participant was also
asked whether she had Internet access
at home and whether she used the
Internet to learn about UAE.
Data were analyzed with use of
Statcalc 1.1 (StatCalc Software, Etext.
net publisher, Venice, CA). Frequency
and percentiles were calculated for
categoric variables. All reported P val¬
ues were based on Fisher exact tests.
The study was reviewed and ap¬
proved by the hospital's human inves¬
tigation committee.

RESULTS
The two survey groups were quite
similar. The mean patient ages were
45.4 years in the first survey and 44.2
years in the second. Seventy-five per¬
cent of respondents to the first survey
and 73% of respondents to the second
survey had earned at least a 4-year
college degree (differences not statisti¬
cally significant, Fisher exact test, P >
.05).

The Table contains the results of
the telephone surveys during both
time frames. There was a significant
difference in the number of gynecolo¬
gists initially opposed to UAE (P <
.05), with fewer gynecologists initially
opposed to UAE in the second survey
in comparison with the first. There
was also a significant difference in the
number of gynecologists who offered
UAE as a treatment option (P < .05),
with more gynecologists offering UAE
as a treatment option in the second
survey in comparison with the first. In
addition, there was a significant differ¬
ence in the number of gynecologists
who initiated discussion of UAE with
their patients (P < .05), with more gy¬
necologists initiating discussion of
UAE with their patients in the second
survey in comparison with the first.
Finally, there was no significant differ¬
ence in the percentage of patients who
did not return to gynecologists who
were initially opposed to UAE when
comparing the two surveys.
Participants in the second survey
were also queried regarding whether
they had the Internet at home and
whether they used the Internet to
learn about UAE. Seventy-one percent
(15 of 21) reported they had Internet
access at home, and 62% (13 of 21)
reported that they used the Internet to
learn about UAE.

DISCUSSION
This study revealed a trend of in¬
creasing acceptance by gynecologists
of UAE for treatment of symptomatic
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uterine fibroids. This research extends
the literature in this area by providing
an examination of gynecologists'
changing opinions of UAE over time.
Because UAE is a relatively new treat¬
ment for uterine fibroids, and because
gynecologists are most often the pri¬
mary physicians who counsel patients
about treatment options, their knowl¬
edge, attitude, and acceptance of UAE
as a treatment modality is of critical
importance.
With regard to specific trends, it
was found that fewer gynecologists
were initially opposed to UAE in the
second survey (33%) than in the first
(76%). In addition, there was a greater
number of gynecologists offering UAE
as a treatment option in the second
survey (38%) than in the first (5%), and
a greater number of gynecologists ini¬
tiated discussion of UAE with their
patients in the second survey time
frame (43%) than in the first (10%).
Despite these significant gains, 62% of
gynecologists still do not offer UAE as
a treatment option for fibroids. This is
disconcerting because informed con¬
sent dictates discussion of all treat¬
ment options.
Although there appears to be an
overall increasing acceptance of UAE
by gynecologists, there was no signif¬
icant difference in the percentage of
patients who did not return to gyne¬
cologists initially opposed to UAE
when comparing the first (50%) and
second (71%) surveys. It may well be
that gynecologists who fail to discuss
UAE or communicate a negative atti¬
tude toward the procedure may risk
losing their patients.
Seventy-one percent of participants
had Internet access at home, and 62%
of participants used the Internet to learn
about UAE. Therefore, if gynecologists
do not discuss UAE as a treatment op¬
tion, it appears that many patients will
learn about the procedure through the
Internet anyway. Up-front physicianconveyed information would promote a
healthier doctor-patient relationship as
well as counter misinformation some¬
times present on unregulated Internet
sites.
There are several limitations to this
study. First, the study was limited to
women's perceptions of their gynecol¬
ogists' opinions of UAE. Therefore, al¬
though patients' perceptions of gyne¬
cologists' opinions of the procedure
are important in that they may impact
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whether patients stay with the same
gynecologists, the results of this study
do not necessarily reflect gynecolo¬
gists' actual opinions of the procedure.
Second, because the study was limited
to women with fibroids that were
symptomatic to the extent that inter¬
ventional treatment was sought, the
results of this study do not necessarily
apply to the gynecologists of women
with fibroids that were asymptomatic
or symptomatic but did not prompt
operative treatment. The treatment op¬
tions and opinions offered by these
gynecologists may have been differ¬
ent. Third, the study was limited to
surveys of women undergoing UAE at
one specific practice site and therefore
may reflect locally but not necessarily
nationally changing trends in gynecol¬
ogists' opinions of UAE.
In conclusion, a trend of increasing
acceptance by gynecologists of UAE
for treatment of symptomatic uterine
fibroids was found. It is recommended
that interventional radiologists treat¬
ing women with UAE work actively to
create positive relationships with gy¬
necologists and make an effort to get
them involved before, during, and af¬
ter the UAE procedure. In this way,
the trend of greater acceptance of this
safe, effective procedure for the treat¬
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ment of this highly prevalent women's
health condition will be enhanced.
8.
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Relationship between Fibroid Location arid Volume, and Fibroid-Related
Symptoms: Oo Position or Size Matter?

@

E.K. Artec, MD, New Haven, CT • R.M. Masheb, PhD * J.S. Poliak, MD • S.M.
McCarthy, MD, PhD • M.G. Tal, MD (Michael.tal@yale.edu)
PURPOSE: To determine the relationship between MRI-determined fibroid
location, largest fibroid volume (LFV) and total uterine volume (TUV), and
fibroid-related symptoms in premenopausal women with symptomatic
uterine fibroids.
METHOD AND MATERIALS: Eighty premenopausal women undergoing
uterine fibroid embolization (UFE) received a pre-procedural pelvic MR1
and self-report questionnaire investigating the frequency of fibroid-related
symptoms, including pain, urinary, bowel, and bleeding symptoms. From
MRIs, the presence of submucosal fibroids (SMF), intramural fibroids with
a submucosal component (TMFSC), intramural fibroids (IMF), Subserosal
fibroids with an intramural component (SSFIC), and subserosal fibroids
(SSF) were noted, and LFV and TUV were calculated. The frequencies of
fibroids in the different locations defined above and the frequencies of
fibroid-related symptoms in the month prior to UFE were calculated.
Statistical analyses were then performed to determine whether there were
relationships between fibroid location, LFV and TUV, and fibroid-related
symptoms.
RESULTS: Ninety-two percent of patients had IMF, 56% had SSF, 26% had
IMFSC, 26% had SMF, and 5% had SSFIC. Pain was associated with the
presence of IMFSC (p=.013). Pain, urinary, bowel, and bleeding symptoms
were not significantly associated with the presence of fihroids in any other
locations. LFV and TUV were significantly correlated with urinary symp¬
toms (p = .017 and p= .007, respectively). There was no correlation between
LFV or TUV and pain, bowel, and bleeding symptoms.
CONCLUSIONS: In premenopausal women with symptomatic uterine
fibroids, there was a significant relationship between fibroids located
intramurally with a submucosal component and pain symptoms, as well as
between fibroid and uterine volume, and urinary symptoms. No other
significant relationships were found.
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092. Relationship between Uterine and Fibroid Volume and FibroidRelated Symptoms and Sexual Functioning in Premenopausal
Women with Leiomyomata
Arleo E.K_1Masheb R.2; Tal M.G.1 1. Department of Radiology, Yale University,
New Haven, CT; 2. Department of Psychiatry, Yale University, New Haven, CT
Objectives: To determine the relationship between uterine and fibroid volume, and
fibroid-related symptoms and sexual functioning in premenopausal women with
leiomyomata.
Methods: Women undergoing UFE for leiomyomata received a pre-operative MRI
and self-report questionnaires. Total uterine volume (TUV) and largest fibroid vol¬
ume were obtained from pre-operative MRIs. Participants completed a question¬
naire of fibroid-related symptoms including pelvic pain, urinary and bowel
symptoms, and bleeding. In addition, participants completed the Female Sexual
Functioning Index (FSFI), an empirically validated measure including subscales
for sexual desire, arousal, lubrication, otgasm, satisfaction, and dyspareurua. The
frequencies of fibroid-related symptoms in the month prior to UFE, and mean
scores for each subscale of the FSFI, were calculated. Relationships between the
two volumes, and the fibroid-related symptoms and FSFI subscales were examined
using Pearson correlation coefficients.
Results: Thirty women with confirmed leiomyomata received pre-operative MRIs
and completed the questionnaires. TIUV was moderately correlated with urinary
symptoms (r=.40) and several aspects of sexual functioning, including sexual de¬
sire, orgasm and dyspareurua (r=.47, .48 and .50, respectively) at least at the .05
level. However, the volume of the largest fibroid did not correlate significantly
with either fibroid-related symptoms or sexual functioning.
Conclusions: TUV, but not fibroid volume, was related to urinary symptoms and
aspects of sexual functioning in premenopausal women with leiomyomata.
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Quality of Life and Sexual
Functioning in Premenopausal
Women With Leiomyomata
Elizabeth Kagan Arleo
Yale University School of Medicine, New Haven, CT

Robin M. Masheb,

PhD,

and Michael Tal,

md

OBJECTIVE: To characterize quality of life and sexual func¬
tioning in premenopausal women with leiomyomata.
METHODS: Women undergoing uterine fibroid embolization
(UFE) for leiomyomata received a preoperative MRI and
health-related quality of life and sexual functioning question¬
naire. The questionnaire contained empirically validated mea¬
sures, including the Short Form 36 (SF-36) and the Female
Sexual Functioning Index (FSFT). Mean scores for each sub¬
scale of the SF-36 and FSFI were calculated and effect sizes were
computed, using norms for healthy and patient populations. In
addition, correlations with total intrauterine volume (TIUV),
obtained from preoperative MRIs, and subscales from the FSFI
were computed.
RESULTS: Forty women with confirmed leiomyomata com¬
pleted the quesdonnaire. Differences in quality of life scores
between women with leiomyomata and the US female popula¬
tion were small. However, differences in sexual functioning
scores between women with leiomyomata and healthy women
were significant on all subscales, at least at the .05 level, with
effect sizes ranging from medium to large ( — 0.42 to —1.16).
Furthermore, women with leiomyomata did not significantly
differ from women with female sexual arousal disorder with
respect to dyspareunia. Among women with leiomyomata,
several aspects of sexual functioning were significantly related
toTTUV, including desire, orgasm, and dyspareunia {P= .026,
.021, and .019, respectively).
CONCLUSIONS: Participants with leiomyomata had healthrelated quality of life comparable to that of the general popula¬
tion. However, their sexual functioning was below that of
healthy women, especially with regard to dyspareunia.
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Abstract No. 238

Reiationship between Uterine and Fibroid Volume, and
Fibroid-Related Symptoms and Sexual Functioning in
PreMenopausal Women with Leiomyomata.

E.K. Arleo, Yale University, New Haven, CT, USA • R.
Masheb • J. Poliak • M. G. Tal
PURPOSE: To determine the relationship between uterine
and fibroid volume, and fibroid-related symptoms and sexual
functioning in premenopausal women with leiomyomata.

MATERIALS AND METHODS: Women undergoing UFE for
leiomyomata received a pre-operative MRI and self-report
questionnaires. Total uterine volume (TUV) and largest fibroid
volume were obtained from pre-operative MRIs. Participants
completed a questionnaire of fibroid-related symptoms
including pelvic pain, urinary and bowel symptoms, nonmenstrual bleeding and hot flashes. In addition, participants
completed the Female Sexual Functioning Index (FSFI)
empirically validated measure including subscales forsexmi
desire, arousal, lubrication, orgasm, satisfaction, and
dyspareunia. The frequencies of fibroid-related symptoms m
the month prior to UFE, and mean scores for each subscale of
the FSFI, were calculated. Correlations between the two
volumes, and the fibroid-related symptoms and FSFI subscab
were then computed.

RESULTS: Thirty women with confirmed leiomyomata
received pre-operative MRIs and completed the
questionnaires. TUV was significantly correlated with unnan
symptoms (p=.038) and several aspects of sexual functioning,
including sexual desire, orgasm and dyspareunia (p=.026, .021
and .019, respectively). However, the volume of the largesi
fibroid was not significantly correlated with either fibroidrelated symptoms or sexual functioning.
CONCLUSION: TUV, but not fibroid volume, was related to
urinary symptoms and aspects of sexual functioning in
premenopausal women with leiomyomata.
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Changing Trends in Gynecologists Opinion of Uterine
Fibroid Embolization (UFE).

9

E.K. Arleo, Yale University, New Haven, CT, USA •M.G.
Tal

fi PURPOSE: To evaluate the current opinion of gynecologists
|| towards UFE, as perceived by patients, and compare it to the
opinion of gynecologists towards UFE two years ago.

i

|- MATERIALS AND METHODS: Twenty-one women that
I underwent UFE between 7/00 to 4/02, completed a telephone
i survey thus far. They were asked what their gynecologists
l; opinions were towards UFE, both before and after the
% procedure. In addition, they were asked if they see the same
|| gynecologists that they saw before the procedure, what
% treatment options were offered to them and whether they or
if their gynecologist initiated discussion of UFE. These data
I were then compared to data obtained previously from 21
1. women that underwent UFE between 8/98 to 7/00.

RESULTS: Thirty-three percent (7/21) of gynecologists
initially opposed or strongly opposed UFE, in contrast to
76% (16/21) of gynecologists from two years ago, this
difference is statistically significant (p<0.05). Seventy-one
percent (5/7) of the patients did not return to the gynecologists
that were initially opposed to the procedure and are now
seeing other gynecologists. This is similar to data from two
years ago, where 89% (8/9) of the patients did not return to
the gynecologists that remained opposed to the procedure.
While all gynecologists offered hysterectomy, just as they did
two years ago, 38% (8/21) also offered UFE, in contrast to
only 5% (1/21) of gynecologists two years ago, the difference
is statistically significant (p<0.05). Forty-three percent (9/
21) of physicians initiated the discussion of UFE with their
patients, a statistically significant increase from two years
ago, when only 10% (2/21) of the physicians initiated
discussion with their patients (p<0.05).

CONCLUSION: More gynecologists are offering UFE as a
treatment option for uterine fibroids and more have a favorable
opinion towards UFE than two years ago. The majority of
patients who underwent UFE whose gynecologist opposed
the procedure did not continue seeing the same gynecologist,
reflecting a similar trend as two years ago.
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A recent study conducted by Dr. Michael Tal and Elizabeth Kaaan Arleo of the
Yale University School of Medicine’s Department of Diagnostic Radiology
presented some positive findings about the efficacy and rates of doctor approval
of uterine fibroid embolization (UFE) for uterine fibroids.
UFE is a minimally invasive procedure that can usually be performed on an
outpatient basis. The procedure involves the use of a catheter that is fed through
the femoral artery to the uterine artery and then used to administer a solution
that blocks blood flow to the fibroid. Because fibroids require a relatively large
quantity of blood to grow and survive in the uterus, blockage of blood flow to
fibroids results in their shrinkage and the disappearance of symptoms for most
patients, without requiring further treatment or the use of more invasive methods,
such as hysterectomy.
The study, published in the December, 2003 issue of the Journal of Vascular and
Interventional Radiology, showed that from 2000 to 2002, patients’ perspectives
about their gynecologists’ opinions of UFE for fibroid tumors changed markedly.
In a 2000 survey of 21 women, three quarters of those surveyed answered that
they thought their gynecologists were opposed to UFE, while in a similar survey
conducted in 2002, only a third of respondents answered that they thought their
gynecologists were opposed to the use of UFE.
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According to Dr. Tal. the jump in the treatment’s popularity can be attributed to
rising doctor and patient awareness, and also to innovations in embolization
techniques and technologies, such as increased research and development of
embolic agents, the solutions made up of tiny plastic particles that flow to
targeted areas, blocking blood supply and thus shrinking fibroids. For this
reason, he believes that doctors should discuss UFE with all patients who suffer
from symptomatic uterine fibroids.
But, adds Ms. Arleo, over half of doctors are still reluctant to recommend UFE as
a treatment option, a trend which she comments, is "disconcerting, especially
since informed consent dictates discussion of all treatment options available."
The pair expressed hope that physicians will increasingly regard UFE as a viable
and advantageous treatment option for patients.
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Description
1) Superselective microcoil embolization for the treatment of lower gastrointestinal hemorrhage is a safe and
effective treatment - study results show a far lower complication rate than surgery. 2) Changing trends in
gynecologists opinions of UAE.
Newswise — Acute lower gastrointestinal hemorrhage (LGI) is a potentially life threatening condition. Most cases
can be managed medically, but 10 - 15 percent require intervention to control the bleeding. The treatment of LGI
hemorrhage has traditionally been surgical and the high morbidity and mortality from bowel resection is welldocumented - as high as 15-30 percent in emergent operations. These patients are usually an older population
at higher surgical risk. Other treatment options also have limitations. Vasopressin infusion, a drug that constricts
the blood vessels, is associated with high rates of rebleeding and multiple side effects. In massive hemorrhage,
endoscopy is limited because the presence of blood and stool may prevent visualization of the source of bleeding.
However, embolization offers a highly effective and minimally invasive treatment to control the hemorrhage.
Because interventional radiologists utilize X-ray imaging to guide the catheter inside the body to the site of
bleeding, visualization in massive bleeding is not an issue.
Superselective embolization involves mechanically blocking the blood flow to the hemorrhage area through the
deployment of tiny coils delivered via a catheter. Interventional radiologists use embolization in many areas of the
body to block blood flow to tumors or to treat traumatic or postpartum hemorrhage. The adjacent blood supply
from non-target vessels continues to provide sufficient blood flow to the affected organ. However, the weaker
blood supply of the LGI tract may predispose the colon to an increased risk of ischemia.
Advances in microcatheter technology such as microcatheters and finer guidewires, coupled with advances in
digital flouroscopic imaging, have resulted in vast improvements in this technique, allowing for superselective -more precise -catheterization while preserving the adjacent blood flow to the bowel.
The study reports the authors’ experience with superselective embolization and a review of the literature. A
combined meta-analysis of 144 superselective microcoil embolizations showed a minimal risk of significant
ischemic complication when a modern transcatheter technique is used. The post-embolic infarction rate was
estimated as zero percent. In light of these results, and until further studies demonstrate a superior alternative
treatment, massive LGI hemorrhage should be treated with attempted superselective microcoil embolization to
control bleeding.
Changing Trends in Gynecologists Opinions of Uterine Artery Embolization for Fibroids: The Patients Perspective
Interventional radiologists at the Yale University School of Medicine surveyed their uterine artery embolization
patients’ to determine their gynecologist’s opinion of uterine artery embolization (UAE), a relatively new treatment
option for uterine fibroids. Traditionally gynecologists have been the providers of treatment for uterine fibroids,
however interventional radiologists perform uterine artery embolization, a minimally invasive procedure that blocks
the blood flow to the fibroid, causing it to shrink. Twenty-one women who underwent UAE between September
1998 and July 2000 and 21 between July 2000 and April 2002 completed questionnaires. Each woman was asked
what her gynecologist’s initial opinion was toward UAE, what treatment options were offered, who initiated the
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discussion of UAE, and whether she continued to use the same gynecologist after UAE.
As of 2002, more gynecologists had a favorable opinion of UAE and were offering it versus in the first survey time
period. In the second survey period, 38 percent were offering UAE as a treatment option, compared with 5
percent in the first survey. Despite this progress, 62 percent of gynecologists still did not offer UAE as a treatment
option for fibroids. This is disconcerting because informed consent dictates discussion of all treatment options.
The majority of patients whose gynecologists initially opposed UAE did not continue to use that gynecologist,
reflecting a similar trend noted two years earlier.
See http://jvir.org for abstracts.

© 2004 Newswise
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BIOSPHERE MEDICAL, (NASDAQ:BSMD), Approximately 20-40
percent of women 35 years and older experience uterine fibroids
and approximately 50% of African-American women have fibroids.
All too frequently, a woman with symptomatic fibroids faces a
hysterectomy or myomectomy to relieve her symptoms caused by
the fibroids. More recently, a minimally invasive procedure called
uterine fibroid embolization (UFE) has become widely available.
UFE, which is performed by an Interventional Radiologist, is a
uterus-saving procedure using a catheter and an embolic agent,
such as BioSphere Medical's Embosphere(R) Microspheres, to cut
off the blood supply to the fibroid tumors. Symptoms, such as
excessive bleeding and pelvic pain, are relieved as the fibroids
shrink.
Some of the initial challenges to the growth of UFE procedures
have been due to a lack of physician and patient awareness.
However, a recent article published in the December 2003 issue of
the Journal of Vascular and Interventional Radiology reveals a
more positive trend for gynecologists to offer UFE as a first line
therapy for fibroid patients, which is expected to help fuel market
growth of this procedure.
Dr, Michaei Tal and Elizabeth Kagan Arleo from the Department of
Diagnostic Radiology, section of Interventional Radiology at Yale
University School of Medicine performed a baseline patient survey
in July 2000 and repeated the survey in April 2002 to investigate if
women believed that their gynecologist were discussing and
offering UFE as a treatment option. Both surveys analyzed the
results of 21 patients, for a total of 42 patients. The survey asked
questions related to their gynecologist's initial opinion of UFE,
which treatment options were offered, who initiated the discussion
of UFE, and whether the patient returned to the same gynecologist
after her UFE. The initial survey in 2000 showed that 76% of their
patient's believed that their gynecologists were opposed or
strongly opposed to UFE as an option. The updated survey in
2002 suggests that only 33% of patients believed that their
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gynecologists were opposed or strongly opposed to UFE. In 2000,
the patients in the survey indicated that approximately 5% of
gynecologists offered UFE as a treatment option whereas in April
2002, this number increases to 38%.
"UFE is clearly a benefit to women who are suffering the
debilitating effects of fibroids, but are hesitant to having major
surgery," indicates Dr. Tal. "The process of performing UFE has
improved tremendously since 1998; thus, gynecologists should be
including UFE in treatment discussions with all fibroid patients.
Interventional radiologists have drastically improved patient care,
pain management, and patient selection over the course of almost
a decade."
Elizabeth Kagan Arleo, fourth year medical student at Yale.
comments, "The fact that 62% of gynecologists still do not offer
UFE as a treatment option is disconcerting, especially since
informed consent dictates discussion of all treatment options
available."
Dr. Tal concludes, "Uterine fibroid embolization is a less invasive
and safer treatment option in women with symptomatic fibroids
than surgery. The trend toward gynecologist acceptance of this
safe procedure should only enhance the patient’s overall quality of
ii

For more information on uterine fibroid embolization, go to
www.ask4ufe.com or call toll free. 1-877-ASK-4UFE.
About BioSphere Medical, Inc.
BioSphere Medical, Inc., based in Rockland, Massachusetts, is a
medical device company focused on applying our proprietary
microsphere technology to medical applications using
embolotherapy techniques. Our core technologies, patented bioengineered polymers and manufacturing methods, are used to
produce miniature spherical beads with uniquely beneficial
properties for a variety of medical applications. Our principal focus
is the treatment of symptomatic uterine fibroids using a procedure
called uterine fibroid embolization, or UFE. Our products are
already beginning to gain acceptance in this rapidly emerging
procedure as well as in a number of other new and established
medical treatments. Our strategy is two fold. First, we are seeking
to grow the embolotherapy business worldwide, specifically the
UFE procedure, by increasing awareness of availability of this
procedure. Second, we are seeking to maintain our current
technology leadership by the continuous introduction of new
products and product improvements, both through internally
developed and externally acquired technologies, that improve and
broaden the use of embolotherapy techniques.
We have received clearance in a number of countries, including
the United States, Canada, Australia and the European
Community, which allow us to sell our products for use in general
embolization procedures, including uterine fibroid embolization.
Cautionary Statement Regarding Forward-Looking Statements -
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Interventional rads pot faith in UFE
marketing, research despite skepticism of
ob/gyns
6/13/03
By: Trade L. Thompson

sponsor

It was less than a decade ago that interventional radiologists reported
their first experience with a new procedure for treating noncancerous
but symptomatic uterine fibroids, or leiomyomas.
French practitioners had been routinely embolizing the uterine arteries
of patients scheduled for myomectomy - seeking to reduce
hemorrhage during the subsequent surgery -- when they noticed that
embolization itself tended to shrink the problematic fibroids. Surgeries
were canceled and a less-invasive treatment was born.
Worldwide as many as 35,000 uterine fibroid embolizations (UFE),
also known as uterine artery embolizations (UAE), have been
performed since then, and the pace quickens every year. Yet UFE
procedures are still dwarfed by long-standing surgical approaches in
the U.S., where every year some 200,000 women undergo
myomectomy or hysterectomy for fibroids.
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A basic diagram of a UFE procedure. A nick is made in the skin and
a catheter is inserted into the femoral artery. The catheter, which is
guided through the artery with real-time imaging, releases tris-acryl
gelatin microspheres into the blood vessel feeding the fibroid. Image
courtesy of SIR.
Interventional radiologists believe many of these patients would be
good candidates for UFE, but the situation is dd)d vu all over again for
radiology. That is, the physicians who "control" most of these patients
generally don’t refer them out.
The American College of Obstetricians and Gynecologists describes

UFE

as investigational in its most recent practice bulletin on the

subject, even though an embolic agent specified for UFE was
approved by the FDA in November. There are also indications that
many gynecologists aren’t even mentioning UFE to patients as a
treatment option - an omission that some observers view as a violation
of informed consent (Clinical Management Guidelines for ObstetricianGynecologists, May 2000, No. 16).
On the other hand, UFE is a relatively new procedure. So until
recently, clinical studies of its performance have been inherently small
and sometimes unflattering.
"I think there is valid scientific caution on the part of gynecologists,"
said Dr. Evan Myers, an associate professor of obstetrics and
gynecology at Duke University Medical Center in Durham, NC, and a
leading public health expert on fibroids.
"But there’s always a bit of a turf battle that goes on," Myers said. "This
is not the first, and not the last time that a new specialty has come out
with a procedure or treatment in an area that has traditionally been that
of another specialty."
The resistance among gynecologists has already spawned a mini¬
revolution in radiology practice, inspiring more interventionalists to
obtain hospital admitting privileges or develop clinics so they can treat
the many

UFE patients who self-refer.

"It has basically forced us into a situation of providing a full clinical
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service," said Dr. J. Mark Ryan, an interventional radiologist at Duke.
"We now have gone back to our roots of being real clinical doctors who
do ward rounds."
In a presentation at the 2003 Society of Interventional Radiology (SIR)
meeting in Salt Lake City, Ryan described his department's relationship
with the ob/gyns as "acrimonious." As a result, his team has developed
and implemented their own post-UFE pain management protocol
without any input from gynecological colleagues (Radiology, August
2002, Vol.224:2, pp.610-613).

"(UFE) allowed us to develop an office practice with consultations and
see patients outside of the hospital, which we hadn’t done before," said
Dr. Neal Joseph, director of the two-year-old South Florida Fibroid
Center in Hollywood "Now, in addition to seeing several fibroid patients
every office day, we’re seeing peripheral vascular patients, renal
patients, oncologic patients, aortic stent graft patients - all for
consultations."
Encouraged by the success to date and the substantial upside potential
of UFE, the interventional radiology community is working to win more
hearts, minds, and patients. Major initiatives include research that will
hopefully sway gynecologists or at least negate their objections,
national information campaigns to educate physicians and the public
about the procedure, and local direct-to-consumer marketing by
individual practitioners and radiology groups.
Quiet epidemic

A major reason for the successful consumer marketing of UFE is that
so many patients are suffering immensely from fibroid symptoms.
These include pain and very heavy bleeding that can cause anemia
and keep women from work and other activities Initial treatment
generally involves oral contraceptives or non-steroidal painkillers,
although these are often insufficient.
Interestingly, although fibroids are by definition a problem of the
childbearing years, removing the uterus is the most common surgical
solution. Fewer than 40,000 myomectomies occur each year in the
U.S., compared to the 150,000 or more hysterectomies performed
annually for the treatment of fibroid symptoms.
In fact, U S. hysterectomy rates have declined only a little over the last
two decades, and remain three times higher than rates in Australia and
western Europe, according to an analysis published last year in the
American College of Obstetrics and Gynecology’s peer-reviewed
journal (Qpstetrics & Gynecoiogy, February 2002, Vol. 99:2, pp. 229234).
"The drivers for innovation tend to be either industry or physician
groups," noted gynecologist and researcher Myers. "Hysterectomy
cures the problem, so there hasn’t been a huge demand, at least from
physicians, for alternative treatments."
At the same time, myomectomy has been far from definitive. Unlike

UFE, which is designed to cut off the blood supply to all fibroids,
surgeons confronted with multiple fibroids at myomectomy must
choose which few to tackle. Interventional radiologists say that many of
their

UFE

patients have previously undergone myomectomy.
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"What we see very often is that the fibroids rapidly go back," says Dr
Steven Janney Smith, director of interventional radiology at LaGrange
Hospital near Chicago. "It almost seems like when you take fibroids out
with myomectomy, you just make more room for the little fibroids."

This pre-embolization, sagittal T1-weighted
midline MR depicts an enlarged uterus with
multiple fibroids highlighted by white arrows.
The black arrow points out the uterus
impinging anteriorly on the bladder neck.
Image courtesy of Dr. Steven Janney Smith.
Many myomectomy patients end up having a hysterectomy. But
interventional radiologists suggest that gynecologists may have
underestimated the number of patients who want to preserve their
fertility, or who have a cultural or personal aversion to hysterectomy.
"What I’ve heard many, many times is, ‘I just don’t want to lose my
uterus. To me it would feel like a castration,’" Ryan said.

The same patient six months after the UFE
procedure. This sagittal, T1-weighted midline
MR image shows a 50% decrease in the size
of the uterus (white arrow). The fibroids have
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low signal (black arrow), consistent with
devascularization. The patient reported
complete relief of symptoms. Image courtesy
of Dr. Steven Janney Smith
Patients are also self-referring for the other benefits of UFE,
interventionalists said As with most interventional radiology
procedures, UFE is less invasive than the surgical alternatives. A
catheter is inserted into the femoral artery and is threaded to the
uterine arteries, where embolizing particles of plastic or gelatin are
released. Hospitalization is usually one night.
After UFE most women can resume normal activity within a week, a
shorter time than some myomectomy approaches and definitely shorter
than the standard six-week recovery after hysterectomy. The shorter
recovery time is appealing for working women and those with families.
Physician shift
Given the pokey evolution of gynecology’s fibroid treatments, it’s
probably not surprising that gynecologists have been slow to even
acknowledge the availability of UFE But change is occurring.
After interventional radiologists at Yale University in New Haven, CT,
began offering UFE in 1998, they started tracking gynecologists’
opinion of the procedure by asking patients about the advice they
received. Among women who underwent UFE at Yale between 1998
and mid-2000, only 10% had learned about the procedure from their
gynecologists.

Pre-UFE angiogram with
catheter insertion. Contrast
highlights fibroids. Image
courtesy of Dr. Neal
Joseph, Radiology
Associates of Hollywood,
FL.
By mid-2000 to 2002, some 43% of the patients treated had heard
about UFE from their gynecologists. But that increase doesn't placate
the researcher who presented the latest findings to the Society of
Interventional Radiology.
"A majority of gynecologists still are not offering uterine fibroid
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embolization
as an option," said Elizabeth K. Arleo, a third-year Yale
medical student. "It’s disconcerting, because informed consent dictates
that all possible treatment options should be mentioned."

The post-UFE image
shows arteries occluded for
a reduction in blood flow to
the fibroids. Image courtesy
of Dr. Neal Joseph,
Radiology Associates of
Hollywood, FL.
Financial self-interest is the driving issue, contends Yale
interventionalist Dr. Michael Tal. "The obstetrics is not as lucrative and
there's a lot of malpractice (insurance costs), so hysterectomy is one of
the main sources of income for gynecologists."
Whatever self-interest they may have, gynecologists are changing their
stated position on UFE. Only 33% of the gynecologists described in
the latest Yale survey were opposed to UFE when it was raised as a
treatment option, compared to 76% two years earlier.
Interestingly, gynecologists may take a financial hit if they oppose

UFE The research also found that patients who underwent the
procedure despite their gynecologist’s opposition were very unlikely to
see that gynecologist again.
Patients first

The evolving opinions of gynecologists probably reflect their increasing
familiarity with UFE, both from national and local sources, Tal said.
There have been more journal articles and news reports, and Tal has
spoken directly to gynecology groups about

UFE.

"Initially, the patients that you will get based on those presentations are
the patients that nobody wants to operate on," Taj said, citing patients
with HIV, hepatitis, obesity, and other comorbidities. Still, "every patient
is a way to capitalize on building a relationship with that specific
gynecologist."
So with every case, Tal_sends the gynecologist copies of all pre- and
post-procedure clinical notes. "The key thing in building a UFE
practice, in my opinion, is to take responsibility for the patient before,
during, and after the procedure, and, while doing this, maintain a
positive and open communication with the gynecologist," he said.
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Even if interventional radiologists have initially taken on new clinical
responsibilities because gynecologists refused to work with them,
continuing with this approach seems logical and appropriate.

"A model where the gynecologist refers the patient to the IR - who then
does the procedure and the gynecologist then handles all the problems
afterward - isn’t going to be very attractive," said gynecologist Myers.

Getting back to basics: Dr. Michael Tat steps out of the
interventional suite to talk with a patient about her UFE options.
Often a woman’s ob/gyn won’t even entertain the subject, so it
may be up to the interventional radiologist to take over. Image
courtesy of Dr. Michael Tal.
Interventionalist Smith agreed: "Why should I make them admit the
patient and do all this if I’m getting paid to do the procedure? It’s not
fair to them."

Total responsibility for the patient also empowers interventionalists to
provide the kind of service that generates good buzz.

"Making sure there are no stones left unturned, making sure that you
are treating the patient for post-procedural pain adequately - basically
making a good experience for patients," said Ryan. "I think that has
been extremely important."

Consumer marketing
Attention to detail does more than generate word-of-mouth business,
Ryan says. Women also share their experiences in Internet health chat
rooms that spread the word much farther and wider.

In fact, the Internet appears to be critical in enabling

UFE to

avoid the

fate of other new procedures that challenged entrenched approaches.
"Women find out information on the Internet and they know what they
want," said Tal. "So the gynecologists have to, and do, adapt to that."

Interventionalists also credit the Web sites developed for their practice
groups with bringing in numerous self-referred patients. "Without it I
don’t know how we would have ever gotten started, since right out of
the box we were kind of viewed as a threat to the livelihood of
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gynecologists," said Smith.
As a new marketing tool for doctors, the Internet also presents some
headaches For instance, Smith was somewhat chagrined when the
Web site developer he hired selected DrFibroid.com as the Internet
address. "It sounds like I’m a used-car salesman," he complained. But
Smith kept the name because at that point, he didn't know that he
could choose another
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The SIR advertising campaign, marketing UFE directly to
patients, generated a significant increase in the number of
procedures performed. Image courtesy of SIR.
Other approaches that interventionalists have used to reach patients
include speaking to women’s groups and inviting local television or
newspaper reporters to see a procedure and interview previous
patients.
Then there is the marketing used by Joseph for the opening of the
South Florida Fibroid Center in 2000. With help from a consultant who
had promoted the University of Miami’s medical facilities, the fibroid
center ran advertisements in major daily newspapers, on cable
television, and on two radio stations whose listeners matched the
demographics of fibroid patients.
The two-month ad campaign worked so well -- especially the radio
spots, which generated 90% of the self-referrals, Joseph said - that the
center did it again a year later.
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"We already had a good baseline, but it gave us another boost of
patients," said Joseph, who also had anecdotal evidence that his 30second descriptions of fibroid symptoms and treatment were being
heard during drive time "I'd come to work and everybody was saying,
"Oh, I heard you on the radio."
The South Florida Fibroid Center is now handling 20 to 25
embolizations a month. Joseph says that results have also influenced
his colleagues at Radiology Associates ot Hoiiywooa. "It’s just got us
into the habit of marketing ourselves and our practice both to
physicians and to the public," he said.
National news
In addition to the marketing by individual UFE practitioners, SIR
recently completed a yearlong public information campaign that
included ads in Ebony magazine, the Journal of Family Practice and
Annals of Internal Medicine, and dissemination of video and print press
releases and public service announcements.
The campaign generated significant increases in traffic to SIR’S call
center and Web site: Phone inquiries went up from 45 to 200 per
month, and hits on the Web site’s UFE "physician finder" went from
25-33 per day to as high as 81 in one day.
Demand for SIR’S information has slowed with the conclusion of its
campaign, although the society continues to provide patient and
physician "Grand Rounds" information both on its Web site and as
handouts for use by its 3,000 members.
The education effort has also been picked up by BioSphere Medical, a
Rockland, MA, company that received FDA approval of its acrylic co¬
polymer embolizing beads in November. BioSphere is now advertising
a toll-free hotline (1-877-ASK-4UFE) and Web site
( www ASK4UFE) through the New York Times and the Wall Street

Journal.
But mass marketing doesn’t always fit comfortably with medicine.
"The problem with any kind of direct-to-patient marketing (by
physicians) is there’s no real oversight of the validity of claims," Myers
said. "Historically, new innovations tend to get marketed very
aggressively, and gynecologists have been guilty of that as well with
various laparoscopic procedures."
Judging UFE
Interventional radiologists agree that their procedure should be
validated through traditional scientific scrutiny, although many argue
that the medical literature already makes an excellent case for UFE’s
safety and efficacy. After all, embolization of the uterine arteries has
been performed for more than 25 years to stem postpartum
hemorrhage, with studies showing successful treatment and
subsequent pregnancies among the patients.
SIR recommends providing referring physicians with studies published
in their specialty journals, such as the series of reports in Fertility and
Sterility on the Ontario Uterine Fibroid Embolization Trial, a prospective
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multicenter study of 555

UFE

patients.

Another popular citation is an article in Obstetrics and Gynecology by
Dr. James Spies and colleagues at Georgetown University in
Washington, DC. It reported on 400 consecutive patients who
underwent embolization, with serious complications for only 1.25% and
a 5% overall periprocedural morbidity rate (July 2001, Vol. 98:1, pp. 2934).
Other articles have reflected less favorably on UFE, including a UCLA
study that found that women were more likely to need further invasive
treatment after UFE than after myomectomy (Obsieirics and
Gynecology, November 2002, Vol. 100:5, part 1, pp. 864-868).
Thus, many UFE providers are participating in further research to
confirm their perception of the procedure. Foremost among these is the
FIBROID registry spearheaded by SIR’S Cardiovascular and
Interventional Radiology Research and Education Foundation
(CIRREF). This registry now includes data on more than 3,000 patients
treated at dozens of sites around the world.
In a talk at the 2003 SIR conference, Dr. Robert Worthington-Kirsch
from the CIRREF FIBROID Registry Steering Committee shared the
latest data on patient demographics and procedure techniques. Boston
Scientific of Natick, MA, and Biosphere provided research funds for the
multicenter registry. Both companies manufacture embolic
microspheres used in

UFE.

This pre-UFE, sagittal FSE MR image depicts a large submucosal
fibroid and several small intramural fibroids. Image courtesy of Dr. J.
Mark Ryan.
"As of August 31,2002, we have 2,605 cases logged," WorthingtonKirsch said. "Of those 2,605 patients, 2,471 have given consent for
long-term follow-up, and 2,300 cases were available for analysis.
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Registry enrollment closed after the first of January with somewhat
over 13,000 patients enrolled. Data has been provided from 58 sites,
52 in the U S., four in Canada, one in the U.K., and one in Hong Kong."
The mean age of the women undergoing UFE was 43.4 with
Caucasians and African-Americans making up the bulk of the patient
population. Comorbidities included obesity, smoking hypertension, and
diabetes In terms of reproductive history, just under half had never had
a child, he said.
"Just over half the patients were evaluated by MRI, and half the
patients were evaluated by either transabdominal or transvaginal
ultrasound. The mean uterine volume was just under 1,300 cc with a
reasonable spread. Half the patients had one or two fibroids; about a
quarter of the patients had five or more fibroids," Worthington-Kirsch
said The majority of patients (85%) complained of menorrhagia. Other
symptoms included bulk or pressure and pain.

This sagittal FSE MR image, one-year post-UFE, shows a marked
reduction in uterine volume and almost complete shrinkage of the
submucosal fibroid, as well as a decrease in the size of intramural
fibroids. Image courtesy of Dr. J. Mark Ryan.
In terms of technique, the primary embolic agent used was calibrated
microspheres in just under 75% of the patients, he reported. In just
over half the patients, microcatheters were used with an average of
about 1.2 catheters per case.
"The mean procedure time was about 55 minutes; the mean
fluoroscopy time was 16.3 minutes, and this agrees with other
procedures of similar difficulty and complexity," Worthington-Kirsch
said. "An average of 64 angiographic images were obtained The
overall technical success was 98%, with both uterine arteries
embolized. Just about everybody received (intravenous) conscious
sedation during the procedure and then most received RCA (patientcontrolled analgesia) narcotics afterward for pain management." The
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average hospital stay was 1.4 days.
The principal investigator for the FIBROID registry is Duke gynecologist
and researcher Myers. He says the database will enable some good
conclusions about the safety of UFE, as a start But it won’t
necessarily enable comparisons with other fibroid treatments.
Myers summarized the problem as lead author of a 2001 report by the
U S. Agency for Healthcare Research and Quality on management of
uterine fibroids: "In general, there was a remarkable lack of high-quality
evidence supporting the effectiveness of most interventions for
symptomatic fibroids."
Still, winning over gynecologists will probably require radiologists to
demonstrate their initiative as researchers as well as clinicians. "I think
if there was good data that this was equivalent to myomectomy, it
would be harder for there to be resistance," Myers said.
Duke’s Ryan is among the interventional radiologists looking to do a
head-to-head trial, assuming that gynecologists will participate after he
publicly criticized their attitude toward UFE.
"You know Osama bin Laden? Well, I came next on the list, pretty
much," said Ryan of the reaction he received. "But things have
evolved, and there’s been generation of mutual respect and greater
appreciation of what we as interventional radiologists do."
By 1 racie L. Thompson
AuntMinnie.com contributing writer
June 13,2003

Additional reporting by Shalmali Pal.
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